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4ABSTRACT
Congenital cytomegalovirus infection (cCMV) is the most common congenital
infection of  the fetus.  It  affects  approximately 6 in 1,000 of  all  newborns in
developed countries. The prevalence varies in different populations. Only a
minority of the infected infants, approximately 10%, have symptoms due to
cCMV at birth. The morbidity among these symptomatic cCMV infants is high;
about half of them will develop permanent long-term sequelae, such as hearing
loss or neurological  impairment.  The majority of  cCMV-infected infants are
asymptomatic, and their prognosis is clearly better. It is estimated, however,
that 10%–15% of the asymptomatic infants also develop some long-term
sequelae due to the infection. Congenital CMV infection is the most common
non-genetic cause of sensorineural hearing loss (SNHL) in young children. In
addition, it is estimated to be the most common infectious cause of intellectual
disability among children.
The seroprevalence of CMV in the population is an important indicator of the
frequency of cCMV. The fetus can be infected in the womb both after maternal
primary and non-primary CMV infection. Primary infection occurs when a
person encounters the CMV for the first time. Non-primary infection means
either a reactivation of a latent virus or a re-infection with a different strain of
the virus in a seropositive person. If the infection is common in the population,
both reactivations and primary infections are subsequently frequent.
We have studied the disease burden of cCMV in Finland. For that purpose, we
evaluated the seroprevalence for CMV in Finland and the outcome of infants
with symptomatic and asymptomatic cCMV infection. We also analyzed
whether  the  maternal  CMV  infection  during  pregnancy  causing  cCMV  was
primary or non-primary.
In the first study, we evaluated CMV seroprevalence and the temporal changes
in the seroprevalence in Finnish pregnant women. We examined CMV serum
antibodies  of  200  randomly  collected  samples  from  the  Finnish  Maternity
Cohort  (FMC)  serum bank  during  three  different  decades:  1992,  2002,  and
2012.  The  seropositivity  rate  decreased  significantly  from  84.5%  (95%  CI
78.7–89.2) in 1992 to 71.5% (95% CI 64.7–77.6) in 2012.
The outcome of symptomatic cCMV infection was evaluated retrospectively
from  a  cohort  of  children  diagnosed  with  cCMV  in  five  Finnish  tertiary
hospitals from 2000 to 2012. The type of the maternal infection was defined
either as a primary or as a non-primary, based on the archived early pregnancy
serum samples.  We identified  29  infants  with  symptomatic  cCMV from the
patient registers. The FMC serum bank sample was available for 26 of them,
5and  the  study  population  comprised  these  26  infants.  The  maternal  CMV
infection during pregnancy had been a primary infection in less than half of
the cases (12/26,  46%).  Any long-term sequelae occurred in 58% (15/26) of
infants, neurologic abnormality in 50% (12/24), and SNHL in 42% (8/19) of
the  children.  Of  the  children  whose  mothers  had  suffered  from  primary
infections in the first trimester, 86% (6/7) developed one or more long-term
sequelae. Of the children whose mothers had experienced non-primary
infections during the pregnancy, 64% (9/14) developed long-term sequelae.
None  of  the  5  children  whose  mothers  had  had  primary  infections  in  the
second or third trimester had developed any long-term sequelae.
To evaluate the prevalence of cCMV in the Finnish population and the outcome
of asymptomatic cCMV infection, we performed a large-scale screening study
in four Helsinki area hospitals from September 2012 to January 2015. Of the
19,868 infants screened with a saliva CMV PCR test, 40 had a confirmed cCMV
infection,  corresponding  to  a  prevalence  of  2  in  1,000  (95%  CI  1.4–2.6).
Maternal CMV infection during pregnancy had been a primary one in 47%
(18/38). We followed the cCMV positive children and healthy control children
for 18 months. The Griffiths Mental Development Scales were used to assess
neurological  outcome.  No  differences  in  the  Griffiths  scales  could  be  found
between cCMV positive and healthy controls at age 18 months. Hearing was
evaluated by transient-evoked otoacoustic emission (TEOAE) and sound field
audiometry  (SF).  Similarly,  the  hearing  outcome of  the  cases  did  not  differ
from that of the healthy controls. None of the children had a bilateral hearing
loss requiring hearing rehabilitation. In addition, no CMV-related findings
were detected in the ophthalmologic examinations.
We evaluated the viral shedding of the cCMV-positive children identified in
screening at  3 and 18 months of  age.  Urine CMV culture was positive in all
samples tested at  3 months (40/40) and at  18 months (33/33).  Saliva CMV
PCR was positive in all 3-month samples (40/40) but in only 24% (9/37) of
18-month samples. We determined the CMV glycoprotein B (gB), gH, and gN
genotypes from the CMV-positive screening samples. All previously described
genotypes except gN2 could be found in our cohort of CMV positive samples.
Mixed infections were uncommon (3/38).
In  conclusion,  our  findings  indicate  that  the  disease  burden  of  cCMV  is
relatively low in Finland. The prevalence was only 2 in 1,000, and the outcome
of the asymptomatic infants was favourable. Although the infection was in
general rare, the morbidity of the symptomatic infection was remarkable. Over
half of the infants from the retrospective cohort with CMV-related symptoms
at birth developed later long-term sequelae. The CMV genotype distribution of
our CMV-positive population without symptoms at birth was similar to that
reported from countries with a higher frequency of CMV infections and does
not therefore explain the low burden of the disease in Finland.
6TIIVISTELMÄ
Synnynnäinen sytomegalovirusinfektio (CMV) on yleisin sikiöaikainen
infektio. Sen esiintyvyys eri väestöissä vaihtelee ja on kehittyneissä maissa
noin 6/1000 vastasyntynyttä. Vain noin 10% sikiöaikana CMV-infektion
saaneista vastasyntyneistä on syntyessään oireisia. Nämä lapset ovat usein
sairaita, ja heistä noin puolelle jää infektiosta johtuva pitkäikaishaitta, kuten
kuulovaurio tai neurologinen vamma. Suurin osa sikiöaikana infektoituneista
lapsista on kuitenkin täysin oireettomia ja heidän ennusteensa on selvästi
parempi. Arviolta noin 10-15%:lle näistä oireettomista lapsistakin ilmaantuu
seurannassa infektion aiheuttamia pitkäaikaispulmia. Synnynnäinen CMV-
infektio on yleisin ei-geneettisen kuulovaurion aiheuttaja. Lisäksi on arvioitu,
että se on yleisin kehitysvammaisuutta aiheuttava infektio.
Sytomegaloviruksen esiintyvyys väestössä vaikuttaa synnynnäisen CMV-
infektion yleisyyteen. Sikiö voi infektoitua kohdussa, mikäli äiti sairastaa
raskausaikana ensi-infektion eli kohtaa CMV:n ensimmäisen kerran. Äidin
aiemmin sairastama, elimistössä latenttina säilynyt virus voi aktivoitua
raskausaikana tai aiemmin CMV-infektion sairastanut äiti voi raskausaikana
saada uuden, toisen viruskannan aiheuttaman tartunnan. Myös näihin
uusintainfektioihin liittyy sikiön infektoitumisen riski. Infektion ollessa
yleinen väestössä, ensi-infektioita ja viruksen reaktivaatioita tapahtuu usein.
Tutkimme synnynnäisen CMV-infektion aiheuttamaa tautitaakkaa Suomessa.
Selvitimme CMV:n esiintyvyyttä väestössä sekä syntyessään oireisten ja
oireettomien synnynnäistä CMV-infektiota sairastavien lasten ennustetta.
Selvitimme, oliko sikiöaikaiseen infektioon johtanut äidin raskauden aikainen
CMV-infektio ensi-infektio vai ei.
Ensimmäisessä osatyössä selvitimme raskaana olevien naisten CMV-
seroprevalenssia ja sen muutoksia. Tutkimme CMV-vasta-aineet 200:sta
satunnaisesti valitusta seerumipankkinäytteestä vuosilta 1992, 2002 ja 2012.
Seroprevalenssi laski vuodesta 1992, 84,5% (95%CI 78,7-89,2) vuoteen 2012,
71,5% (95%CI 64,7-77,6). Muutos oli tilastollisesti merkitsevä.
Oireisen CMV-infektion taudinkuvaa selvitimme retrospektiivisesti. Haimme
Suomen yliopistosairaaloiden potilasrekistereistä ne lapset, joilla oli vuosina
2000–2012 diagnosoitu oireinen synnynnäinen CMV-infektio. Selvitimme
äidin raskauden aikaisen CMV-infektion luonteen alkuraskauden
seeruminäytteistä. Yhteensä 29 synnynnäistä CMV-infektiota sairastavaa lasta
oli syntynyt ko ajanjaksolla. Tutkimukseen otettiin mukaan ne 26 lasta, joiden
kohdalla alkuraskauden seerumipankkinäyte oli käytettävissä äidin CMV-
infektion ajankohdan selvittämiseksi. Äiti oli sairastanut CMV-ensi-infektion
7vajaassa puolessa tapauksista (46%, 12/26). Seurannassa oireisista lapsista
58% (15/26) kärsi jostain pitkäaikaispulmasta, 50%:lla (12/24) oli
neurologinen poikkeavuus ja 42%:lla (8/19) oli kuulovaurio. Niistä lapsista,
joiden äiti oli sairastanut CMV-ensi-infektion ensimmäisen
raskauskolmanneksen aikana, 86%:lla (6/7) esiintyi joku pitkäaikaisongelma.
Lapsista, joiden äidillä oli raskauden aikana ollut latentin infektion
reaktivaatio tai uuden kannan aiheuttama uusi infektio, 64%:lla (9/14) esiintyi
seurannassa poikkeavuus. Kenelläkään niistä viidestä lapsesta, joiden äiti oli
sairastanut CMV ensi-infektion alkuraskauden jälkeen toisessa tai
kolmannessa raskauskolmanneksessa, ei todettu seurannassa poikkeavuutta.
Laajassa seulontatutkimuksessa selvitimme synnynnäisen CMV-infektion
esiintyvyyttä väestössä ja oireettoman infektion taudinkuvaa. Seuloimme
vastasyntyneitä neljässä Helsingin alueen synnytyssairaalassa syyskuusta
2012 tammikuuhun 2015 syljestä otettavalla CMV-nukleiinihapon
osoitustestillä. Yhteensä 19 868 lasta osallistui seulontaan ja näistä 40:lla
todettiin varmennettu CMV-infektio, joten esiintyvyys väestössämme oli
2/1000 (95%CI 1.4-2.6/1000). Äiti oli sairastanut CMV-ensi-infektion
47%:ssa (18/38) tapauksista. Seurasimme tutkittavia 18 kuukauden ikään asti.
CMV-positiivisten lasten ja terveiden verrokkien välillä ei todettu eroa
suoriutumisessa Griffithsin kehitysseurantamenetelmän testeissä. Myöskään
kuulontutkimuslöydöksissä (otoakustinen emissio, äänikenttä-audiometria)
ei todettu eroa CMV-positiivisten ja terveiden verrokkien välillä. Kenelläkään
ei todettu kuulonkuntoutusta vaativaa molemminpuoleista kuulovikaa.
Silmälääkärin tutkimuksessa ei todettu CMV-infektioon liittyviä löydöksiä.
Selvitimme seulonnassa diagnosoitujen CMV-positiivisten lasten viruseritystä
3 ja 18 kuukauden iässä. Virtsan CMV-viljely oli positiivinen kaikissa
tutkituissa näytteissä 3kk (40/40) ja 18kk (33/33) iässä. Syljen CMV-testi oli
positiivinen kaikissa 3 kk näytteissä (40/40) mutta vain 24%:ssa (9/37) 18 kk
näytteitä. Selvitimme CMV:n glykoproteiinien B (gB), gH, ja gN genotyyppejä
CMV-positiivisista seulontanäytteistä. Lukunottamatta gN2 genotyyppiä,
kaikkia muita aiemmin kuvattuja genotyyppejä löytyi aineistossamme.
Sekainfektiot olivat harvinaisia (3/38).
Tutkimustemme mukaan synnynnäisen CMV-infektion aiheuttama
tautitaakka oli Suomessa suhteellisen pieni. Esiintyvyys oli ainoastaan 2/1000
ja oireettomien lasten ennuste oli aineistossamme suotuisa. Vaikka infektio oli
kokonaisuudessaan harvinainen, oireisen infektion aiheuttama sairastavuus
oli huomattavaa. Retrospektiivisessa aineistossamme yli puolella syntyessään
oireisista lapsista oli joku pitkäaikaispoikkeavuus. CMV:n genotyyppien
jakauma seulonta-aineistossamme oli samankaltainen kuin väestöissä, joissa
synnynnäistä infektiota on kuvattu esiintyvän enemmän. Täten genotyyppien
jakauma ei selitä synnynnäisen CMV-infektion vähäistä tautitaakkaa
väestössämme.
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1 INTRODUCTION
Cytomegalovirus (CMV) is a ubiquitous virus, presenting all over the world. In
most  countries,  the  infection  is  acquired  before  adulthood.  When acquiring
CMV infection for the first time, the person experiences a primary infection.
After primary infection, the host gets viremic, and the virus can be excreted to
bodily  fluids  such  as  saliva,  urine,  genital  secretions,  and  breast  milk  for
variable periods of time. After primary infection, the virus remains latent in
the body and can recurrently be reactivated and thus shed through excretions
again.
Primary CMV infection in immunocompetent children and adults  is  usually
asymptomatic or presents with flu-like symptoms. Most CMV seropositive
persons have encountered the infection without knowing it. In
immunocompromised individuals, neonates, or a developing fetus, the virus
may cause clinical disease and lead to significant morbidity.
The fetus can be infected already in the womb if the mother has either primary
or non-primary CMV infection during pregnancy. Non-primary infection
means that the seropositive mother has either reactivation of the latent
infection or encounters a new infection with a new strain of the virus.
CMV infection is the most common congenital infection in developed
countries.  It  has  been  considered  the  most  common  infectious  cause  for
intellectual  disability.  It  is  also  the  most  common  non-genetic  cause  of
sensorineural hearing loss in small children. Only a minority of infants with
congenital CMV infection (cCMV) have symptoms at birth. Symptomatic
cCMV  has  high  long-term  morbidity.  About  half  of  the  infants  with
symptomatic cCMV will develop some long-term sequelae due to the infection.
The  majority  of  infected  children,  however,  appear  healthy  at  birth.  The
prognosis  of  these  asymptomatic  infants  is  much  better,  and  they  usually
recover without sequelae. The reasons for the great variability of cCMV-related
sequelae, from no symptoms in most cases, to severe mental retardation and
deafness in some cases, is not clear.
Due to the disease burden of cCMV, developing a vaccine for CMV has been
advocated as a high priority. However, major obstacles in vaccine development
exist, and after decades of research, there is still no vaccine on the market. In
order to identify asymptomatic infants, universal screening of all newborns
has been suggested to allow early interventions. To evaluate the benefits of
possible  future  vaccinations,  or  universal  screening  of  all  newborns,  it  is
essential to know the local burden of cCMV. In this thesis, we have evaluated
the disease burden of cCMV in Finland.
Review of the literature
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2 REVIEW OF THE LITERATURE
2.1 CYTOMEGALOVIRUS
2.1.1 HISTORY
Doctor Hugo Ribbert was the first one to notice large inclusion bodies in the
kidneys in a stillborn infant with syphilis in 1881. He reported the findings in
1904 [1]. He could, however, interpret these finding only after Jesionek and
Kiolemenoglou had described similar findings in the lungs, kidneys, and liver
of  an  8-month  old  fetus  [2,  3].  In  1950,  Wyatt  et  al  introduced  the  term
“Cytomegalic inclusion disease” [4]. They described the postmortem findings
in  six  infants  with  the  inclusion  disease.  After  reviewing  the  literature  of
previously  described  cases,  the  authors  concluded  that  the  etiological  agent
must  be  a  specific  virus  infecting  fetus  and  infants.  The  morphology  and
cytology of the inclusion-bearing cells is pathognomonic of the disease [4, 5].
The virus was later isolated in 1956/57 by several researchers [6-8]. In 1965,
Klemola  and  Kääriäinen  recognized  CMV  as  a  cause  of  mononucleosis-like
illness [2, 9].
2.1.2 STRUCTURE
Human  CMV  is  a  double-stranded  DNA  virus.  It  belongs  to  the  beta-
herpesvirus family and is the largest herpesvirus. The schematic structure of
CMV is presented in Figure 1. CMV is composed of three layers. In the middle
is the nucleus with the genome packed tightly in an icosahedral protein capsid,
surrounded by a proteineus tegument layer that is enclosed by a lipid envelope
[10, 11]. The nucleus contains a 235-kilobase genome with over 166 genes. The
genome consists of two regions: unique long (UL) and unique short (US). The
genes are named by prefix from the location (UL/US) and a sequential number
[12]. Tegument contains proteins such as pp65, pUL47, pUL48, pp150, pp28,
and pp71. Tegument proteins have a role in stabilizing the structure, delivering
the viral genome to the nucleus, viral replication, and immune evasion. The
outermost  lipid  envelope  contains  several  glycoproteins  that  associate  in
complexes and play a role in virus–host interaction [13, 14].
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Figure 1 Schematic structure of cytomegalovirus
2.1.2.1 Strains/Genotypes
There is  a  wide variability  in the genome of  CMV. It  has been hypothesized
that  the  genetic  polymorphism  in  the  viral  genes  encoding  for  proteins
involved in the host immune response and virulence factors may contribute to
the  variability  of  clinical  outcome  of  cCMV  [12].  However,  the  evidence
supporting this hypothesis is controversial [15-27].
Variability occurs in the CMV genes encoding for envelope glycoproteins gB
(UL55),  gH  (UL75),  gN  (UL73),  and  gO  (UL74), and cytokine/chemokine
homologs, tumor necrosis factor-Į like receptor gene (UL144), Į-chemokine
genes UL146 and UL147, and functional ǃ-chemokine receptor US28. These
genes have been used to define different genotypes and strains of the virus.
The virus can be genotyped for one or more genes. The generally approved
consensus defining clinically relevant strains is still lacking [12].
The presence of more than one genotype in one sample, reflecting mixed
infection  with  several  strains,  is  common  among  immunocompromised
individuals [28-31]. Mixed infections also exist in cohorts of congenitally
infected  infants  [15,  32-36].  However,  the  clinical  role  of  mixed  infections
versus an infection caused by a single strain is  open.  Mixed infections have
occurred among infants with both non-symptomatic and symptomatic cCMV
[15, 32-36].
2.1.2.2 Glycoproteins gB (UL55), gH (UL75), and gN (UL73)
Envelope glycoprotein B (gB) is  the major component of  the lipid envelope.
The gene coding for gB is UL55. This protein is highly conserved in all herpes
Review of the literature
18
family viruses. It is thought to be essential for the life cycle of the virus. It has
an important role in both the virus entry and cell-to-cell spreading of the virus
[37]. Four main gB variants, gB1–gB4, have been identified.
Envelope  glycoprotein  H  (gH)  and  its  complexes  with  other  surface
glycoproteins are involved in the fusion of the viral and host cell membranes.
This step is essential for the entry of viral material into the cell [38, 39]. The
gene coding for gH is UL75. Two variants, gH1 and gH2, have been identified.
Envelope glycoprotein N (gN) is essential for virus replication. It is involved in
virus attachment to the host after forming a highly immunogenic complex with
glycoprotein gM [40-43]. The gene coding for gN is UL73. The glycoprotein
gN is highly polymorphic and 7 gN genomic variants have been identified: gN-
1, gN-2, gN-3a, gN-3b, gN-4a, gN-4b, and gN-4c [40, 44, 45].
Both  gB  and  the  pentamer  complex  containing  gH  are  also  highly
immunogenic and have been used in vaccine development as potential
antigens [46].
2.2 EPIDEMIOLOGY
CMV exists all over the world and causes congenital and acquired infections.
The seroprevalence for CMV among women of reproductive age in different
populations is presented in Table 1. It has been lowest in western European
countries such as France (46%), Ireland (37%), and the Netherlands (37%)
[47-49]. In many areas, especially in developing countries, the prevalence has
been very high and approaches 100% [50-52]. In Finland, the seroprevalence
among pregnant women has been 56.3%–76.4% [53,  54].  Seropositivity has
been associated with socioeconomic factors; that is, it is higher among people
with lower socioeconomic status [53, 55-57].
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Table 1. CMV seroprevalence among women of child-bearing age in different
populations.
Location CMV seroprevalence Population studied Year / ref
Norway 54% Pregnant women 2018/[58]
Sweden 72% Pregnant women 2008/[59]
United
Kingdom
(UK)
77.1% All
49% White British women
89% South Asian origin, born in UK
98% Born in Asia
Pregnant women 2013/[60]
Ireland 37% Women age 20-39 y 2016/[48]
France 45.6% All
27.6%-48.6% Born in Western
country
96.6%-99.5% Born in non-Western
country
Women age 15-49 y 2017/[47]
Germany 51.7% Women age 18-45 y 2018/[61]
Italy 79.9% Pregnant women 2006/[62]
Portugal 75.5%-81.5% Women age 20-44 y 2011/[63]
The
Netherlands
36.9% Dutch / Western origin
85.1% Non-Western migrants
Women age 20-45 y 2015/[49]
Austria 73.2% All
53% Born in Western Europe
92% Born in Eastern Europe
96% Born in Middle East
Pregnant women 2015/[64]
United
States (USA)
61.3% All
55.8% Born in USA
90.2% Born outside of USA
Women aged 20-49 y 2016/[65]
China 96.2% Infant DBSa 2017/[51]
Japan 69.1% Pregnant women 2015/[66]
Iran 92% Blood donors and
healthy subjectsb
2015/[67]
Yemen 91.3% Pregnant women 2016/[68]
Mexico 89.6% Pregnant women 2018/[69]
Brazil 98.1% Pregnant women 2018/[52]
DBS=Dried blood spot, y=years
aIgG measured in infant’s blood sample reflect maternal IgG transferred through placenta during
the third trimester
bMeta-analysis
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2.2.1 PREVALENCE OF CONGENITAL CMV
CMV  is  the  most  common  cause  of  congenital  infections  in  developed
countries. In universal screening studies from mainly industrialized countries,
the overall prevalence of cCMV has been 0.64%–0.7% [70, 71]. The prevalence
of cCMV infection is known to correlate with the seroprevalence of CMV in the
population. The higher the seroprevalence, the higher the prevalence of cCMV
[70,  72,  73].  This is  in contrast  to the epidemiology of  two other pathogens
causing congenital infections: Rubella and Zika viruses. It has been shown that
incidence of  congenital  Rubella and Zika infections dramatically  drops after
the seroprevalence in a community has reached a certain level. This is
explained by the protective role of specific antibodies [74, 75]. However, two
features  in  CMV are  different  from Zika  and  Rubella.  First,  CMV immunity
does not give full protection against re-infections with different strains.
Second,  after  the  primary  infection,  CMV remains  in  the  host  as  a  life-long
latent infection leading to recurrent reactivations and shedding of infectious
virus.
The  prevalence  of  cCMV  in  different  populations  is  presented  in  Table  2.
Maternal seroprevalence in the community affects the prevalence of cCMV,
meaning that also prevalence for cCMV is higher in communities with a low
standard of living, crowded accommodation, and lower hygienic standards
[70]. In older studies, the screening was performed with CMV culture-based
regimens,  which  are  time  consuming  but  serve  as  the  gold  standard  in
assessing cCMV infection. Polymerase chain reaction (PCR)-based methods
have  replaced  the  culture  in  most  cohorts.  PCR,  however,  is  sensitive  to
contamination and the proportion of false positives has been high in studies
with confirmatory sampling. In the study from Portugal reporting high cCMV
prevalence of 10.1 in 1,000, the screening was performed from the archived
DBS cards [76]. Due to the study design, resampling could not be performed,
but the original  samples were studied in triplicate and the positive samples
were retested for confirmation [76]. In other studies reporting high prevalence
of 10 and 12 in 1,000 in Brazil, all PCR-positive samples were either retested
[77]  or  confirmed  by  CMV  culture  [78].  In  addition,  PCR-based  screening
studies in a CMV-seropositive population identified a very high cCMV
prevalence in Gambia (54 in 1,000) and in China (61 in 1,000) [79, 80]. Both
presented populations with a very low standard of living. Coexisting infections
may influence the prevalence, as active placental malaria infection correlated
with cCMV infection in Gambian cohort. However, in these two studies from
Gambia  and  China,  control  sampling  was  not  performed,  and  thus  false
positives may have influenced the findings. The lack of infrastructure may also
affect the quality of diagnostics in developing countries.
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Table 2. Prevalence of cCMV and proportion of symptomatic cCMV in different countries.
Country (ref)
Screening
method
Individuals
screened, n
Prevalence,
n/1,000
Proportion of
symptomatic (%)
UK [81] Throat swab
culture
4,178 1.7 NA
UK [82] Throat swab
culture
14,200 3  12% (5/42)
Ireland [83] Urine or saliva,
PCR
1,044 1.9 0/2
Italy [84] Saliva culture 1,268 4.7 0/6
Italy [62] DBS, PCR 9,032 1.8 13% (2/16)
France [85] Saliva, PCR 11,715 3.7 20% (9/44)
Portugal [76] DBS, PCR 3,600 10.1 NA
Belgium [86] Urine culture 14,021 5.3 5% (4/74)
The
Netherlands
[87]
DBS, PCR 6,433 5.4 NA
Sweden [88] Urine culture 16,474 4.6 22% (17/76)
Slovenia [89] Urine PCR 2,841 1.4 0/4
Israel [90] Saliva 9,845 4.9 22% (10/46)
USA [91] Saliva rapid
culture and/or
PCR
100,332 3.9 9% (28/313)
Japan [92] Urine culture 11,938 3.1 14% (5/37)
Japan [93] Urine on filter
paper, PCR
21,272 3.1 30% (20/66)
Japan [94] DBS, PCR 1,176 1.7 0/2
Japan [95] Urine, PCR 23,368 2.6 3% (2/60)
Japan [96] Urine on filter
paper, PCR
6,348 5 50% (16/32)
Japan [97] Urine on filter
paper, PCR
2,193 4.6 40% (4/10)
Brazil [78] Saliva or urine,
PCR
12,295 10 10% (12/121)
Brazil [98] Saliva, urine
PCR
1,200 12 4% (1/25)
China [51] Saliva or DBS,
PCR
10,933 6.9 3% (2/75)
China [79] Urine PCR 1,159 61 24% (17/71)
Iran [99] Urine PCR 1,617 4.9 38% (3/8)
India [100] Saliva PCR 750 4 33% (1/3)
Gambia [80] Urine PCR 741 54 NA
NA=not available
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2.2.2 TRANSMISSION
2.2.2.1 Horizontal transmission
After primary CMV infection, infectious virus is shed to blood, saliva, urine,
breast  milk,  sperm,  and  the  cervix.  The  primary  infection  leads  to  life-long
latency, and the infection can periodically reactivate to cause recurrent viral
shedding [14, 101]. Transmission occurs horizontally from person to person or
vertically from mother to the fetus.
Young children are regarded as the main reservoir  of  infectious virus in the
community. Young children acquiring the infection in early years or already
during their fetal life continue to excrete the virus for long periods of time, up
to  several  years.  Excretion  is  common  during  the  second  year  of  life  and
gradually becomes less common during later years in childhood [81, 101-105].
However, recurrent shedding has also been reported in the adult population
[106, 107]. Children attending daycare centers were more often shedding
(13%–83%)  compared  to  those  who  were  taken  care  of  at  home  [102-105].
Especially  for  pregnant women, the main source of  the infection is  infected
toddlers [14, 101].
2.2.2.2 Vertical transmission
If  the  mother  has  contracted  the  virus  during  pregnancy  and  develops  a
primary  CMV  infection,  the  overall  risk  of  a  fetal  infection  is  about  40%.
Transmission rates vary, however, according to the trimester of pregnancy:
37% in the first trimester, 40% in the second trimester, and 65% in the third
trimester [108, 109]. On the other hand, if the mother is already CMV-positive
before pregnancy, the fetus can be infected due to reactivation of maternal
latent infection. In addition, the seropositive mother can be re-infected by a
new strain  of  CMV.  In  the  case  of  a  non-primary  infection,  the  risk  of  fetal
infection has been estimated to be 0.5%–3.4% [70, 110, 111]. In non-primary
infections, the risk of infection of the fetus is thus much lower compared to the
primary infection. Non-primary infections are, however, relatively common
among pregnant women, and a significant proportion of congenital infections
are due to maternal non-primary infections [73, 85, 97, 112, 113].
2.2.2.3 Virus transmission and circulation in the community
CMV  circulates  ubiquitously  in  the  community,  since  the  CMV  positive
individuals continue to shed the virus for a long time and recurrent shedding
occurs. The circulation of the virus in the community is presented in Figure 2.
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Figure 2 Simplified figure on routes of CMV transmission in the community. Young children
are the main reservoir of infectious virus leading to horizontal transmission. Transmission
occurs after exposure to secretions containing viruses, such as breast milk (breastfed
infants), saliva and urine (all age groups), and genital secretions (perinatal infections,
sexually active teenagers, and adults). Transmission through blood transfusion and solid
organ transplantation is also possible.
2.3 PATHOGENESIS
Due to its  broad tropism, CMV may infect  almost all  cell  types in the body,
causing a wide spectrum of end organ diseases. The virus can replicate at least
in  epithelial,  endothelial,  macrophage,  and  dendritic  cells  as  well  as  in
parenchymal  and  connective  tissue  cells  of  almost  all  organs.  However,  the
immune system of immunocompetent hosts can limit the infection in the early
phase,  and  the  primary  infection  is  usually  asymptomatic.  Primary  CMV
infection induces both innate and adaptive immunity [114-116].
The virus enters the body through body surfaces after direct contact with virus
containing secretions. The various membrane proteins, membrane
glycoproteins, and the established glycoprotein complexes are essential for
HCMV entry into the cells. After binding to cell surface receptors, the virion
envelope fuses with the cellular membrane and the nucleocapsid is released
into the cell. In the cytoplasm, the nucleocapsid is actively transported toward
the nucleus. Viral gene expression starts after the viral genome has reached
the nucleus. New nucleocapsids with viral DNA are produced in the nucleus
and are then encapsulated in two steps starting in the nucleus and completed
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in  the  cytoplasm.  Mature  virions  are  transported  to  the  cell  surface  and
released from the cell [13, 14, 114, 117].
In spite of the robust immune response after primary infection, CMV is able to
establish  a  life-long  latency.  The  mechanism  of  latency  is  not  completely
understood. During the latent infection, the viral genome is in episomal form
in  the  human cell  and  lytic  infection  is  inhibited.  Suppression  of  the  major
immediate early promoter is  essential  for  keeping the virus in latent phase.
CMV  latency  occurs  at  least  in  myeloid  lineage  cells,  myeloid  dendritic
progenitors, and peripheral monocytes. Latency may also occur in endothelial
and neuronal progenitors [118, 119]. Recurrent reactivations with production
of infectious virus occur only in differentiated macrophages and dendritic cells
[114, 119]. The reactivation is normally suppressed by the immunoresponse of
the  immunocompetent  host.  Long-term  memory  T  cells  have  an  important
role in preventing clinical disease after recurrent reactivation of the virus
[116].  However,  in  the  case  of  immunosuppressed  individuals  or  pregnant
women with a developing fetus, uncontrolled viral replication can take place
and lead to major morbidity.
Several  pathological  mechanisms  are  involved  in  fetal  damage  caused  by
intrauterine CMV infection. Both direct cytotoxic effect of the virus, as well as
immunoresponse  of  the  host  are  involved  in  the  cellular  damage.  CMV
infection may modify apoptotic  and cell  cycle pathways that  are essential  to
normal  embryogenesis.  Endovascular  injury,  as  well  as  placental  infection
leading  to  placental  insufficiency,  may  lead  to  hypoxia  in  the  developing
organs [120, 121].
2.4 ACQUIRED CMV INFECTION
2.4.1 IMMUNOCOMPETENT INDIVIDUALS
CMV infection in immunocompetent individuals is usually a benign self-
limiting condition with mild, if any, symptoms. Most primary infections in
adults, and especially among pregnant women, are asymptomatic. The
symptoms  that  do  occur  can  be  unspecific  such  as  fatigue,  malaise,  fever,
myalgias, headache, night sweats, and hepatitis. CMV can cause a
mononucleosis-like  illness  with  a  milder  pharyngitis  and  lymphadenopathy
compared with mononucleosis caused by Epstein-Barr virus [122-125]. In
immunocompetent children, the disease is usually mild and most infections
are asymptomatic. Some severe CMV-induced pneumonias have been
reported also in immunocompetent children [126, 127]. In most cases,
however, CMV detection in the bronchoalveolar fluid of a previously healthy
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child indicates a reactivation of a latent infection, not acute CMV infection
[128]. CMV can also cause hepatitis, which is usually a self-limited condition
[129, 130]. CMV infection may induce thrombocytopenia either through direct
infection of megakaryocytes or an indirect immunomediated mechanism [131-
133]. In adults, CMV has been associated with venous thromboembolic events
such as splanchnic vein thrombosis, with a favourable outcome in most cases
[134, 135]. In addition, CMV has been identified as a causative agent in colitis.
Among immunocompetent persons, the interpretation of positive CMV
detected  in  the  colitic  gut  is  not  always  clear.  The  virus  can  be  either  an
innocent  bystander  or  a  sign  of  an  undiagnosed  immunodeficiency.  In  rare
cases, it is the only cause of the colitis [136, 137].
2.4.2 IMMUNOCOMPROMISED INDIVIDUALS
The  CMV infection  causes  significant  morbidity  and  mortality  both  in  solid
organ transplant and hematopoietic stem cell transplant (HSCT) recipients
and  other  patients  with  immunocompromised  status  [138,  139].  In  the
pediatric population, infants with severe primary immunodeficiency such as
severe combined immunodeficiency (SCID) are especially vulnerable to CMV.
The prevention of infection before stem cell transplantation is essential, since
the  outcome  of  HSCT  has  been  worse  in  children  with  SCID  and  active
infection at the time of transplantation [140, 141].
CMV infection in immunocompromised persons can present as a systemic
disease or an end-organ CMV disease of almost any organ, such as pneumonia,
gastrointestinal disease, hepatitis, retinitis, encephalitis, nephritis, cystitis,
myocarditis, and pancreatitis. The diagnosis is based on the clinical signs and
symptoms of the organ together with viral detection. Serology is not reliable in
assessing the history of CMV infection in severely immunocompromised
patients,  as  they  do  not  always  develop  CMV-specific  antibodies.  In  case  of
retinitis,  the  clinical  picture  itself  is  so  typical  that  an  experienced
ophthalmologist can recognize the infection without isolation of virus [138].
Both primary and recurrent infections may cause disease in
immunocompromised individuals. Clinical symptoms correlate with the viral
load. Thus, low-grade viremia may be asymptomatic and high viral load
usually correlates with severe symptoms. Pre-emptive antiviral therapy of
asymptomatic viremic patients with immunosuppression does reduce cases of
severe CMV disease [138, 142].
2.4.3 PERI- AND POSTNATAL INFECTIONS IN NEONATES
The transmission from mother to neonate can occur perinatally from genital
secretions, or postnatally. The most common source of postnatal infection is
Review of the literature
26
breast milk. Sensitive PCR techniques have detected CMV or CMV DNA in
67%–97% of the milk of CMV seropositive mothers [143-150]. Of the preterm
infants who received untreated breast milk of seropositive mothers, 19%
acquired postnatal CMV infection [151]. The proportion ranged from 6%–37%
in different cohorts [145, 151-155]. Less data has been reported from term
infants.  Granström  et  al  evaluated  148  mother  child  pairs  in  Finland,  and
postnatal CMV infection had occurred by 4 months of age in 38% of breastfed
children  whose  mother  was  seropositive  [156].  In  an  African  study  by
Musonda  et  al.,  the  transmission  of  CMV was  associated  with  the  length  of
breast feeding in a seropositive, HIV-negative population [150]. CMV infection
occurred  by  the  age  of  18  months  in  110/119  (92%)  of  the  children  who
continued to receive breast milk at the age of 18 months, and in 25/32 (78%)
of the children who were breast fed for less than one year [150]. The postnatal
infection is usually asymptomatic. In premature infants, however, symptoms
are  more  common.  Any  CMV-related  symptoms,  including  blood  count
abnormalities, petechiae, hepatomegalia, hyperbilirubinemia, elevated
transaminases,  jaundice,  or  CMV-pneumonia,  occurred  in  0%–89%  of
premature infants with acquired CMV infection. A sepsis-like syndrome,
however, was less common, occurring in 0%–25% of the infected preterm
infants [145, 152-155]. Cases of colitis due to post- or perinatal infection have
been described, but these cases are extremely rare [157]. In some studies,
postnatal  CMV  infection  among  preterm  infants  has  been  associated  with
inferior neurological outcome [158, 159]. In most studies, however, the post-
and perinatal infection did not affect the long-term outcome or cause hearing
loss [148, 155, 160-163].
2.5 CONGENITAL CMV INFECTION
2.5.1 MANIFESTATIONS
Transmission  of  CMV  infection  can  occur  transplacentally  from  mother  to
developing  fetus  leading  to  cCMV.  Most  children  with  cCMV  infection  are
totally asymptomatic at birth. Only about 10%–15% of infants with cCMV have
symptoms due to the infection. It is important to differentiate these two
subsets of cCMV, symptomatic and asymptomatic infection. These are two
different entities with different outcomes of the disease. Symptomatic cCMV
infection  can  be  a  multisystem  disease  affecting  several  organs,  or  a  more
isolated disease with symptoms limited to only one end organ [164-168]. The
apparent symptoms typical for cCMV infection are growth restriction,
microcephaly, hepatosplenomegaly, jaundice, petechiae, and central nervous
system (CNS) abnormalities [164-166, 168-170]. The skin may present with
blue-red maculopapular lesions because of extra medullary hematopoiesis in
the dermis [169, 171]. Pneumonitis is a rare manifestation of cCMV [167].
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Imaging and laboratory testing may reveal thrombocytopenia, neutropenia,
anemia, elevated liver enzymes, and CNS abnormalities like intracerebral
calcifications, ventriculomegaly, cystic malformations, and neuronal
migration abnormalities. On further evaluation, sensorineural hearing loss,
chorioretinitis, optic atrophy, and retinal hemorrhage may be detected [164-
166, 168-170]. The symptoms in cohorts of symptomatic cCMV are presented
in Table 3.
Table 3. Clinical findings of infants with symptomatic cCMV infection.
Manifestation Proportion Reference
Prematurity 21%–50% [164-166, 168]
Growth restriction 27%–50% [164-168]
Microcephaly 20%–53% [164-168]
Hepatosplenomegaly 22%–60% [164-167]
Elevated transaminases 17%–83% [164-166]
Jaundice 37%–67% [164, 166, 167]
Conjugated hyperbilirubinemia 47%–69% [164, 165]
Thrombocytopenia 50%–77% [164-167]
Petechiae 45%–76% [164, 165, 167]
Purpura 13% [164]
Central nervous system abnormality 37%–68% [164, 167]
Hearing loss 18%–59% [165-168]
Chorioretinitis 14%–17% [165, 167, 168]
Pneumonitis 7% [167]
2.5.2 DIAGNOSIS OF CONGENITAL CMV
Diagnosis  of  cCMV infection  in  neonates  is  based  on  detecting  the  virus  by
culture, or parts of the virus genome by PCR-based methods, during the first
3 weeks of life. The rapid CMV urine culture is based on detecting CMV early
nuclear antigen in urine by an immunofluorescence test [172]. CMV DNA can
be detected in saliva or urine by real-time PCR [173, 174]. In research settings,
the DBS collected from newborns for metabolic screening have been used for
testing  by  real-time  PCR  for  CMV.  This  testing  has  variable  sensitivity
depending  on  the  assay  and  is  not  standardized  for  clinical  use  [175-178].
Perinatal and postnatal infections are very common and lead to CMV shedding
in  urine  and  saliva  about  3  weeks  after  transmission.  The  positive  samples
collected after the age of 3 weeks cannot differentiate between the congenital
and post/perinatal infections.
Review of the literature
28
Serologic testing is not appropriate in diagnosing cCMV infection. During the
last trimester, maternal IgG antibodies are transferred from the mother to the
fetus, thus the IgG antibodies measured from infants reflect the antibody
status of the mother. IgM antibodies are larger in size and are not transferred
through placenta. The neonates, however, do not produce IgM antibodies in
all cases of infection. The sensitivity of CMV IgM testing has been only 49%–
71% in cCMV [179-181].
2.5.3 IMAGING IN CONGENITAL CMV
In  order  to  evaluate  the  CNS  findings  of  the  cCMV,  brain  imaging  is
mandatory. Normal imaging findings predict good neurological outcome [167,
182]. Typical neuroimaging abnormalities due to cCMV infection include
calcifications, cysts, ventriculomegaly, abnormalities in sulcation and
gyration, delayed myelination, hypoplasia of corpus callosum, cerebellar
abnormalities, and white matter abnormalities [167, 182-185].
Cerebral ultra sound (US) is an easy, non-invasive examination. It is suitable
for  screening  of  major  abnormalities.  It  has  good  accuracy  in  detecting
periventricular and parenchymal calcifications, cysts, and abnormalities in
ventricle size. However, it does not detect migration or myelination
abnormalities  or  white  matter  defects.  Posterior  fossa,  cerebellum,  and
subtentoria  spaces  are  also  not  well  visualized  with  US.  Minor  non-specific
abnormalities with ambiguous significance such as lenticulostriatal
vasculopathy and germinolytic cysts can be detected with US. Computerized
tomography (CT),  on the other hand,  has a good capacity for evaluating the
gross structural abnormalities and calcifications. For a developing brain,
however, the radiation exposure is high and CT is no longer recommended.
Magnetic  resonance  imaging  (MRI)  has  the  best  accuracy  in  finding  the
migration and white matter abnormalities but is not as sensitive in showing
calcifications as US or CT [183-185].
2.5.4 OUTCOME OF CONGENITAL CMV
2.5.4.1 Hearing
SNHL is the most common long-term sequela of cCMV, affecting 9%–22% of
all children with cCMV [59, 78, 86, 91, 92, 95, 186-189]. The pathogenesis of
CMV-related hearing loss remains unclear. The virus and inflammation are
present in the structures of inner ear [190, 191]. Virus has been identified in
the stria vascularis, supporting cells of the organ of Corti, in the vestibule and
non-sensory epithelium, as well as in the endolymphatic sac [190, 191]. These
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structures regulate the endolymphatic secretion and potassium balance. It is
hypothesized  that  abnormal  potassium  homeostasis  may  have  a  role  in  the
pathogenesis of progressive and late-onset hearing loss in these children [190,
191].
According to the meta-analysis, hearing loss has appeared in 12.6% (95% CI
9.4–16.3)  of  cCMV  infants  identified  from  universal  screening  [192].  The
impairment  has  been  far  more  prevalent  after  symptomatic  cCMV  (32.8%,
95%  CI  23.2–43.2)  than  asymptomatic  cCMV  (9.9%,  95%  CI  6.3–14.2).  In
different cohorts of infants identified in screening, the prevalence of SNHL
among symptomatic infants has varied from 22%–55% and among
asymptomatic from 5%–21%, presented in Table 4 [59, 78, 86, 91, 92, 95, 186-
189]. In cohorts of more selected patient groups such as referrals and infants
diagnosed based on clinical symptoms, the proportion of hearing loss among
symptomatic cCMV has been higher, up to 67% [193-195].
SNHL may be late onset, appearing during the first months or even years of
life.  Hearing  loss  can  be  also  progressive  or  fluctuating.  In  a  meta-analysis
presenting data on cCMV-associated hearing loss among both screening and
clinical cohorts, late-onset hearing losses constituted 18.1% of hearing losses
in symptomatic and 9% in asymptomatic cCMV [192]. The majority of hearing
losses detected in symptomatic children were bilateral (71.2%), in contrast to
otherwise asymptomatic children with mostly unilateral hearing loss (56.9%)
[192]. SNHL seems to be as common in the groups of babies infected due to
maternal primary as non-primary infections [86, 188, 196].
Hearing  loss  is  less  common  among  the  cohorts  of  children  identified  by
screening, than in cohorts presenting data from clinical series. In screening,
the mildly affected children with better  prognosis  are identified [197].  Also,
the methods for assessing hearing loss and length of follow-up may result in
different findings on hearing outcomes observed. In the earlier studies, before
launching  the  universal  hearing  screening,  the  neonatal  hearing  data  from
otherwise asymptomatic infants was more likely to be unavailable, compared
to the recent studies.
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Table 4. Screening studies presenting prevalence of sensorineural hearing loss among
children with symptomatic (sympt) or asymptomatic (asympt) cCMV, listed in order according
to the location of the study.
Location Follow-up
time
Number of
cCMV subjects
Proportion of cCMV children
developing hearing loss in
follow-up
Reference
Sympt/ All All Sympt Asympt
USA 72
months
53/388
(13.7%)
15.4% 36.4% 11.3% Fowler [186]
USA 34
months
18/76 (23.7%) 15.8% 44.4% 7% Boppana [187]
USA 59
months
33/300 (11%) 10.7% NA NA Ross [198]
USA 4 years 19/296 (6.4%) 8.7% 31.6% 7.2% Ross [91]
Sweden 1-5 years 9/43 (20.9%) 9.3% 22% 5.9% Harris [189]
Sweden 2-4 years 0/12 18.2% - 18.2% Engman [59]
Belgium 33
months
3/60 (5%) 21.7% 33% 21% Foulon [86]
Japan 7 years 0/17 11.8% - 11.8% Numazaki [92]
Japan NA 1/53 (1.9%) 9.4% NA NA Yamaguchi [95]
Brazil 47
months
11/85 (12.9%) 11.8% 54.5% 5.3% Yamamoto [78]
Sympt=symptomatic, asympt=asymptomatic, NA=not available
2.5.4.2 Neurology
Congenital CMV infection may lead to neurological abnormalities ranging
from mild behavioral impairments such as attention deficit hyperreactivity
disorder (ADHD) to severe intellectual disability, and motor deficits including
cerebral  palsy.  There  are  at  least  three  mechanisms  that  may  cause  the
damage: uncontrolled viral replication in brain tissue causing damage,
immunomediated damage, and placental infection leading to placental
insufficiency and thus hypoxic brain damage [121].
In cohorts of symptomatic infants, the proportion of neurological
abnormalities ranges from 25%–80% [96, 199, 200]. The proportion of
sequelae in symptomatic infants has been lower in screening studies compared
to the cohorts evaluating clinically diagnosed cCMV infants [197]. As discussed
earlier, the children with only mild or isolated symptoms with better prognosis
can easily be missed without screening.
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The proportion of neurologic sequelae among asymptomatic children has been
reported  to  be  much  lower,  up  to  14.5%  [92].  Interestingly,  many  studies
comparing neurological outcome of asymptomatic cCMV children and healthy
controls did not find a difference between groups [194, 201-205]. Lopez et al
observed no difference in academic achievements among the 89 asymptomatic
cCMV children with normal hearing compared to 40 controls [206]. The
follow-up was long (median 13 years), and the study comprised almost all of
the  infants  originally  identified  in  the  screening  (89/92).  Another  study  by
Pearl  et  al  with  a  follow-up  of  2  years  did  not  find  a  difference  in
neurodevelopment  assessed  in  36  asymptomatic  infants  with  cCMV and 74
controls [204]. In a study from China by Zhang et al, on the contrary, the 49
children with asymptomatic cCMV had significantly lower verbal and full-scale
IQs  compared  to  50  healthy  controls  at  48  to  72  months  of  age  [79].  The
Chinese  study  was  performed in  an  area  with  high  incidence  of  intellectual
disability;  however,  such  disability  was  not  more  common  among  cCMV
infants than controls [79]. Other studies comparing the outcome with controls
had either a small number of participants or a high proportion lost to follow-
up [92, 202, 203, 207]. In Ahlfors’s study, the children with cCMV without any
CNS symptoms at birth had significantly more abnormalities in
neurodevelopment (18.3%, 11/60), compared to controls (2.6%, 1/39)
evaluated  at  7  years  of  age  [88].  However,  these  children  were  not
asymptomatic, since many of them had symptoms outside of CNS after birth.
The neurologic outcome in cohorts of cCMV children identified in screening
studies is presented in Table 5.
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2.5.4.3 Ophthalmology
Visual impairment has been detected especially among symptomatic infants.
In a cohort of 48 congenitally infected children, 39% (7/18) of symptomatic
infants had a fundoscopic abnormality at neonatal period and 22% (4/18) had
a visual impairment at a later follow-up visit at 16 to 72 months of age. None
of the 30 asymptomatic infants had ophthalmologic findings either at neonatal
or  later  examinations  [208].  In  another  study  by  Jin  et  al,  26%  (15/67)  of
symptomatic and 5% (5/95) of asymptomatic infants had visual impairments
at follow-up. Only mild impairments appeared in the asymptomatic infants, as
opposed to symptomatic infants with mostly severe impairments (10/15)
[209].  In  a  long-term  study  by  Lanzieri  et  al.  evaluating  only  symptomatic
infants,  52%  (39/76)  had  ophthalmologic  abnormalities  [210].  Vision  was
normal in 67% (44/66), whereas 21% (14/66) were severely impaired or blind
[210]. The most common ophthalmological abnormalities reported among
cCMV patients were retinal scars, optic nerve hypoplasia, microphthalmia,
strabismus, and cortical visual impairment [208-212].
2.5.4.4 Other problems related to congenital CMV
Other non-specific symptoms such as balance disturbances and feeding
problems have been associated with cCMV infection as well [213]. In addition,
tooth pathology, such as discoloration and enamel abnormalities, have been
reported [214].
2.5.4.5 Outcome in maternal primary and non-primary infection
It had previously been assumed that maternal non-primary infections are less
severe and seldom cause harm to the infant [215]. However, this finding has
been  questioned  in  several  studies  [198,  200,  208,  216-219].  Symptomatic
cCMV seems to be equally  common among children infected after  maternal
primary and non-primary infections, occurring in about 10% of infected
infants  [188,  219].  Similarly,  the  long-term  sequelae  are  common  in  both
groups  [219].  Hearing  loss  developed  on  average  in  11%  of  children  after
maternal primary infection and 14% after maternal non-primary infection
[219]. Other neurodevelopmental abnormalities developed in 9% of children
in primary infections in contrast to 39% in the non-primary group [88, 198,
216, 217, 219].
There are several studies where a large cohort of newborns has been screened
for cCMV and the type of  maternal  infection has been categorized as either
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primary or non-primary. The maternal non-primary infections accounted for
20%–93%  of  the  pregnancies  leading  to  cCMV  [78,  85,  88,  113,  200].  In  a
Brazilian study, 93% (40/43) of cCMV infants were infected after maternal
non-primary infection [216]. Hearing loss developed in a third (1/3) of infants
infected after maternal primary infection in contrast to only 15% (6/40) of
infants infected after maternal non-primary infection [216]. In London, only
20% (13/65) of maternal infections were non-primary [200]. Of the children
infected  after  maternal  non-primary  infection,  15% (2/13)  had  moderate  or
severe abnormalities in long-term follow-up, in contrast to only 6% (3/52) in
the primary group [200]. In a Swedish study of 76 cCMV infants identified in
screening, the type of maternal infection could be determined to be primary in
48% (30/62) and non-primary in 52% (32/62) [88]. Neurologic abnormalities
in follow-up until 7 years of age occurred in 19% (5/27) after primary infection,
and 26% (6/23) after  non-primary infection [88].  In a recent French study,
nearly  half  (48%,  21/44)  of  cCMV  children  identified  in  screening  had
acquired infection after  maternal  non-primary infection [85].  Four children
had SNHL identified after birth: two in children infected after maternal
primary, and two after maternal non-primary infection [85]. In Greece, 90%
(9/10)  of  cCMV  children  identified  after  screening  of  2,149  neonates  were
infected due to maternal non-primary infection, all asymptomatic [113]. Two
of  the  5  children  at  follow-up  had  eventually  developed  hearing  loss,  both
infected after maternal non-primary infection [113].
In the analysis of only symptomatic infants identified in screening in
Birmingham, Alabama, maternal infection was either confirmed or presumed
non-primary in 60% (12/20) of the cases [217]. Of the children with follow-up
data,  any  long-term  sequelae  occurred  in  75%  (6/8)  in  the  non-primary
infection group: intellectual disability in 57% (4/7), motor abnormalities or
chorioretinitis in 13% (1/8), and SNHL in 0/8 children. In children affected
after  maternal  primary  infection,  38%  (3/8)  had  sequela:  13%  (1/8)  motor
abnormality and 29% (2/7) SNHL [217]. In another study from Birmingham,
Alabama, the hearing outcome was analysed in 300 cCMV children identified
in screening with preconceptional and prenatal serum samples available for
categorization of maternal infection [198]. Most children, 59% (176/300) were
infected due maternal primary infection. Hearing loss was as common in both
groups. SNHL occurred in 10% after maternal non-primary, and 11% after
primary infection. However, the hearing loss was more often progressive and
severe/profound in the primary infection group [198].
In an Italian cohort of cCMV referrals (diagnosed based on clinical symptoms
or  known maternal  CMV infection),  an  impaired  neurological  outcome was
observed in 24% of children in primary infection and 25% in non-primary
infection.  Similarly,  hearing  loss  was  equally  common  occurring  in  26%  in
both groups [220].
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2.5.4.6 Viral loads and outcome
The outcome of cCMV infection varies substantially, from asymptomatic
infection to severe permanent damage. As presented earlier in this literature
review,  the  presence  of  clinical  symptoms  at  birth  has  been  the  major
prognostic factor. In several studies, the measured viral loads have been higher
among the symptomatic than asymptomatic children [181, 187, 221, 222]. The
viremia  level  and  length  of  viral  excretion  could  theoretically  be  factors
influencing the long-term outcome also among asymptomatic infants. One
mechanism of CMV-induced pathology that has been hypothesized is the
direct  cytopathic  effect  of  the  ongoing  viral  infection.  The  higher  levels  and
longer time for viral replication could explain a more massive cytotoxic effect.
However, studies have shown controversial findings. In a study by Forner et
al, the viral load measured in the blood of asymptomatic infants was
significantly higher among children who developed sequelae (mean 17,045
copies/ml) than children without sequelae (mean 1770 copies/ml) (p<0.05)
[223].  In  that  study,  the  proportion  of  long-term sequelae  was  30%,  higher
than in most studies among asymptomatic infants. All included children were
born after maternal primary infection [223]. In another study by Zavattoni et
al, however, the viremia level among 89 asymptomatic infants was not
significantly correlated to the progression of long-term symptoms [181]. In a
study from Alabama, the viral load measured during the first 2 months of life
was not associated with hearing loss in symptomatic or asymptomatic children
[221],  nor  was  the  viral  load  in  CMV-positive  DBS  cards  associated  with
development of SNHL [91]. These findings are discordant to the earlier partly
overlapping but smaller cohort from Alabama by the same group, where the
viral  load  in  the  urine  and  peripheral  blood  was  associated  with  the
development of SNHL in otherwise asymptomatic infants [187]. In that study
by Boppana et al, however, no association of viral loads and SNHL was
observed among symptomatic infants [187].
Forner et al did not find a significant difference in the length of viral excretion
in blood or urine between the children with long-term sequelae and the
children  without  sequelae  [223].  Noyola  et  al  reported  that  children  with  a
shorter duration of viral shedding were more likely to develop hearing loss, in
contrast to Rosenthal et al, who found an association between longer duration
of excretion and development of hearing loss [224, 225].
In  summary,  according  to  the  literature,  the  viral  loads  tend  to  be  higher
among symptomatic  infants,  but  the  level  of  CMV DNA measured  in  either
symptomatic or asymptomatic infant is not a good single predictor of later
sequelae at follow-up.
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2.6 TREATMENT, PREVENTION, AND SCREENING FOR
CONGENITAL CMV
2.6.1 TREATMENT OF CONGENITAL CMV
In 1997, Whitley et al published a non-randomised phase II treatment study
of severely neurologically affected cCMV infants. The 6 weeks of intravenous
ganciclovir treatment showed stabilization of hearing loss and better
neurologic outcome in the follow-up compared to historical cohorts [226].
Later in a phase III study, by Kimberlin et al (2003), cCMV infants with CNS
involvement were randomised to receive a 6-week course of intravenous (IV)
ganciclovir  or  no  treatment  [227].  In  the  treatment  group,  none  of  the  25
babies in the ganciclovir group had a worsening in hearing at 6 months of age
compared  with  41%  (7/17)  of  the  non-treated  babies.  However,  when  the
hearing was assessed again at the age of one year or older, 21% (5/24) in the
ganciclovir group had developed further hearing impairment, compared to the
baseline assessment. In the non-treated patients, as many as 68% (13/19) had
hearing deterioration in the better ear from baseline to the second evaluation
at the age of one year or older. None of the 19 non-treated babies and only 17%
(4/24) of the treated babies had improved hearing in the second evaluation,
compared to the baseline level [227]. The neurodevelopmental outcome was
also better  among the treated babies at  the age of  6 months and 12 months
[228].
Kimberlin  et  al’s  finding  that  the  initial  response  of  IV  ganciclovir  was
favourable but later  was diminished raised question about the length of  the
treatment. Was 6 weeks enough? Could a longer treatment better prevent
further deterioration of the hearing? Amir et al later published retrospective
data  on  23  patients  treated  with  a  longer  course  of  antivirals  in  Schneider
Children’s Medical Center in Israel. All their patients had CNS affision before
therapy  and  were  treated  with  a  12-month  protocol:  6  weeks  IV  ganciclovir
followed by oral valganciclovir until the age of 12 months [229]. The full 12-
month treatment was finished by 19 of 23 infants. The authors compared the
hearing  results  with  the  previous  cohort  of  Kimberlin  [227]  with  a  6-week
treatment with IV ganciclovir. The selection for treatment and follow-up
regimen were similar in the cohorts. The hearing outcome at the age of one
year or older was better in Amir’s cohort of longer treatment (p=0.001) [229].
The question of short versus long treatment protocols were investigated in a
large randomised controlled trial (RCT) published in 2015 [230]. Kimberlin et
al  compared  a  6-week  treatment  to  a  treatment  of  6  months  with  oral
valganciclovir. There was no difference in the occurrence of adverse effects
between the groups. The hearing outcome was equal after the 6-month follow-
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up,  but  modest  benefit  in  the  longer  treatment  group  compared  to  shorter
treatment was noticed in the 12-month and 24-month hearing follow-ups. The
significant difference was observed when the number of children with either
normal  or  improved  hearing  was  compared  to  the  number  of  children  with
either worsened hearing or the same degree of hearing loss as at baseline. The
difference  was  statistically  significant  only  in  the  analysis  adjusted  for  CNS
involvement at baseline. It has to be noted, that despite randomisation, there
was some bias in the baseline characteristics of the treatment groups, which
may influence the results. At baseline before treatment, 74% (32/43) of the 6-
month therapy group had normal hearing in the best ear, compared to only
58% (25/43) of the 6-week treatment group. Only 7% (3/43) of children in the
6-month treatment group had severe hearing loss at baseline, in contrast to
19% (8/43) in the 6-week therapy group [230].
The children in the 6-month group had significantly better  outcomes in the
language composite and receptive-communication scale in the Bailey-III
scales at 24 months of age. That difference was seen in the groups of children
with and without baseline CNS affision [230].
Ganciclovir and valganciclovir are potentially toxic drugs inducing
neutropenia in a notable proportion of treated patients [226, 227, 229, 230].
In  animal  models,  there  have  been  worries  about  ganciclovir  having
gonadotoxic effects. The effects have not been demonstrated in humans.
Rodents exposed to ganciclovir in utero or treated with high-dose ganciclovir
have shown abnormal testicular size, histology, and impaired spermatogenesis
[231-234].
Based on the current evidence of limited benefits from antiviral treatment and
potential severe adverse effects, the guidelines suggest offering antiviral
treatment  only  to  cCMV  children  with  moderate  to  severe  symptoms  [235,
236].
2.6.2 PREVENTION OF CONGENITAL CMV
Since the therapeutic options to prevent CMV-related disabilities are limited,
measures to prevent maternal infection during pregnancy have been essential.
The prevention of primary CMV infections by hygienic measures have been
evaluated in several studies [237-239]. These measures included washing
hands after exposure to children’s excretions, avoiding saliva contact with
children, such as kissing on the mouth, sharing utensils, washcloths, and food
and drink, and not sleeping in the same bed with a child. In a study by Adler
et al, the seroconversion rates were examined among women pregnant or
attempting  pregnancy  who  had  a  young  child  attending  daycare  [237].  The
seroconversion rate was same in the intervention group receiving information
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on how to prevent child-to-mother transmission as in the control group, 7.8%
(9/115) and 7.8 (5/51), respectively [237]. In another study by Valoup-Fellous
et  al,  5,173  pregnant  women  were  tested  for  CMV  antibodies  at  around  12
weeks gestation [238]. Seronegative pregnant women were counselled for
CMV and preventive measures. Based on interpreting avidity testing, primary
infection had occurred in 0.42% of women in early pregnancy before 12 weeks
gestation. However, seroconversion occurred in only 0.19% (5/2,583) of
seronegative mothers after 12 weeks gestation. The authors conclude that the
counselling  after  known  seronegativity  could  have  reduced  the
seroconversions  in  later  pregnancy  [238].  Revello  et  al  evaluated  the
seroconversion rates among seronegative pregnant women who were
counselled for CMV and preventive measures at 12 weeks gestation [239]. The
seroconversion rates were compared to those of women who were not
counselled but whose early pregnancy samples were available for assessing
retrospectively whether seroconversion had occurred between 12 gestational
weeks and delivery [239]. Seroconversion was observed in 1.2% (4/331) in the
intervention group and 7.6% (24/315) in the control group (p<0.001),
demonstrating that the intervention of sharing information on CMV and on
prevention of transmission was efficient in reducing new infections [239].
Vaccines to prevent CMV infections have been under development for more
than 50 years without success. The main goal in vaccine development has been
the prevention of cCMV infections, but other aims such as preventing CMV-
induced  complications  among  transplant  patients  also  exist  [46].  However,
vaccine development is complicated by the fact that natural immunity does not
give protection for recurrent infections and fetal disease. The risk for materno-
fetal transmission, however, is reduced by the existing maternal antibodies.
The goal could be to prevent primary infections among pregnant women. In
addition, through herd immunity the total burden of CMV in the community
could be diminished, thus reducing potential CMV exposure among pregnant
women [46].
Administering CMV hyperimmunoglobulin (CMV-HIG) to reduce the risk of
fetal  infection  or  to  diminish  the  symptoms  of  infected  infants  in  cases  of
maternal primary infection during pregnancy has been investigated. In 2005,
Nigro et  al  published a non-randomised prospective study where CMV-HIG
was  offered  to  women  with  primary  CMV  infection  during  pregnancy.  The
transmission risk in the HIG group was lower (16%) than that in non-treated
mothers  (40%)  [240].  Later  in  a  case-control  study,  the  same  author
retrospectively compared the factors of cCMV children with sequelae and
cCMV children without sequelae. HIG treatment was an independent
predictor of better outcome [241]. A retrospective study evaluated the
pregnancies treated with off-label CMV-HIG in four countries in Europe from
2006 to 2010 [242]. The vertical transmission rate was 20.8% after primary
infection in the first trimester and 26.6% after primary infection in the second
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trimester. These transmission rates were lower than in most earlier published
cohorts. The variation in the previous studies, however, has been wide as well:
36% (22.2%–42.2%) after the first trimester and 40.1% (26.9%–44.9%) after
the second trimester [108]. In a prospective study, CMV-HIG was offered to
mothers with primary infection early in the pregnancy, and the outcome was
compared to pregnancies without HIG treatment. The non-treated
pregnancies mainly occurred before the HIG protocol had started [243]. The
outcome in children of the treated mothers was better. At 1-year follow-up, an
adverse  outcome was  observed  in  43% (16/37)  of  infants  born  to  untreated
mothers compared to only 13% (4/31) of treated mothers [243].
However, the major problem in all these non-randomised studies has been the
selection bias of treated/non-treated women. The first and only randomised
trial of CMV-HIG was published in 2014 by Revello et al [244]. It showed no
benefit of the treatment. Adverse outcomes were significantly more common
in the pregnancies after HIG treatment [244]. Women (n=124) with primary
CMV  infection  at  5  to  26  weeks  gestation  were  randomised  to  receive  HIG
treatment (n=61) or placebo (n=63) every 4 weeks until 36 weeks gestation. In
the  treatment  group,  30% (18/61)  were  infected,  and  in  the  placebo  group,
44% (27/62) of fetuses were infected. The difference was not statistically
significant. However, the proportion of obstetrical complications (e.g.,
prematurity, preeclampsia, fetal growth restriction) was significantly higher in
the HIG group (13%, 7/53) than in the placebo group (2%, 1/51) (p=0.06)
[244]. In summary, there is no good evidence to support the usage of HIG to
prevent vertical transmission.
2.6.3 SCREENING FOR CONGENITAL CMV
Most children with cCMV are asymptomatic. Therefore, testing only children
with suspected CMV infection finds only a small proportion of all infected
infants [197, 245]. Universal screening would enable detection of all affected
infants. Testing mothers for CMV antibodies in early pregnancy enables
identification of seronegative mothers at risk for CMV primary infection
during pregnancy. Furthermore, serial testing will reveal new
seroconversions. However, serological screening of mothers fails to identify
the infants at risk of infection due to maternal non-primary infections. Two
strategies for neonatal screening have been used: universal screening and
targeted screening. In targeted screening, the children who fail the newborn
hearing screening are tested for CMV. In universal screening, all children are
tested. Targeted screening is no doubt less expensive compared to universal
screening. It, however, identifies only those children with CMV-related early
onset hearing loss and fails to recognize those children who develop hearing
impairments later in the infancy [247].
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The early identification of all infected infants would allow early interventions.
On one hand, selected infants could benefit from antiviral therapy. On the
other  hand,  the  early  diagnosis  would  improve  the  possibilities  to  start
rehabilitation early, in case of hearing loss, visual abnormalities, or
neurological problems associated with cCMV [248, 249].
Universal hearing screening already detects the cCMV children with early
onset hearing loss, and screening for cCMV would not give an extra advantage.
However, the children who develop late-onset hearing loss soon after birth
would benefit from the early diagnosis. In an analysis comparing children born
before and after universal hearing screening, the early detection of bilateral
hearing loss before 9 months of  age was associated with significantly better
language abilities [248, 250].
As  regards  to  neurologic  abnormalities,  the  early  diagnosis  enables  more
careful follow-up of the affected infants, and early rehabilitation could be
offered in case of developmental abnormalities. Nevertheless, the
developmental and cognitive abnormalities among asymptomatic infants are
only  slightly  more  common  than  in  the  general  population.  In  Finland,  all
children undergo regular developmental assessments according to national
guidelines in the primary care and rehabilitation is provided if needed. Thus,
an early diagnosis of asymptomatic CMV cases might not have a major effect
on later developmental problems. However, one potential benefit of screening
is that the time window for reliable diagnosis is during the early weeks of life
only. If the delayed development is noticed later, when peri- or postnatal
infection may have occurred, congenital infection cannot be excluded by any
laboratory  method.  In  these  cases,  the  diagnosis  of  cCMV  infection  in
screening would be helpful for families, and some other unnecessary
ethiological testing might be avoided.
There  is  evidence  of  antiviral  medication  leading  to  better  hearing  and
neurocognitive prognosis in symptomatic children with cCMV [227, 228, 230].
Symptomatic infection can be identified clinically without screening. There is
no data, however, supporting the treatment of asymptomatic infants with
antivirals.  The early diagnosis,  with the current evidence,  would not lead to
interventions preventing the development of late-onset hearing loss or
impaired neurological outcome among asymptomatic infants.
There are several aspects to questioning universal screening. First of all, it
would potentially cause anxiety in many families. This is an important issue,
especially since there is no effective intervention to prevent long-term
sequelae  among  asymptomatic  infants.  Second,  a  vast  majority  of  these
asymptomatic infants heal without any sequelae.
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The cost-benefit analysis of both targeted screening and universal screening
has indicated some cost savings in the American healthcare system. However,
since the evidence of potential long-term benefits of antiviral treatment is not
strong, these analyses contain many assumptions [251, 252].
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3 AIMS OF THE STUDY
The aim of the study was to evaluate the disease burden of cCMV infection in
Finland (Figure 3). The specific aims of the study were to:
1. Evaluate the CMV seroprevalence among Finnish pregnant women and
analyse the changes in seroprevalence during recent decades (I)
2. Evaluate the prevalence and outcome of asymptomatic cCMV infection
in the Helsinki area, among children diagnosed from screening (III)
3. Evaluate the long-term outcome of symptomatic cCMV infection
diagnosed in Finnish University Hospitals in 2002–2012 (II)
4. Evaluate the type of maternal infection (primary / non-primary) in the
pregnancies leading to symptomatic or asymptomatic cCMV infection
(II, III)
5. Describe  the  subsequent  viral  shedding  in  urine,  saliva,  and  plasma,
and describe the patterns of CMV gH, gB, and gN genotype distribution
among congenitally infected infants identified in screening (IV)
Figure 3 The aim of the study was to evaluate the disease burden on cCMV in Finland.
Disease burden is a multifactiorial entity consisting of features in the population, hosts, and
pathogens.
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4 MATERIALS AND METHODS
4.1 PATIENTS AND POPULATION
Study I
The CMV seroprevalence was evaluated from serum samples from the Finnish
Maternity Cohort (FMC) serum bank. The maternal sera were originally drawn
for the purposes of screening for HIV, syphilis, and hepatitis B at the end of
the first trimester in routine antenatal care. After informed consent, the
leftover sera were stored in a national serum bank at the National Institute of
Health and Welfare, for later research purposes. The bank contains about 90%
of the antenatal sera sampled in Finland. For our study, 200 samples per time
point  (1992,  2002,  and  2012)  were  randomly  selected  using  SPP  statistical
software.
Study II
In study II, we retrospectively reviewed the patient data from children
diagnosed  with  cCMV  infection  from  2000  to  2012.  The  patients  were
identified  through  a  database  search  of  all  University  Hospitals  in  Finland
(Helsinki, Tampere, Turku, Oulu, and Kuopio) after searching for
International Classification of Diseases, 10th Revision (ICD-10) code P35.1,
cCMV  infection.  We  included  in  the  analysis  only  children  with  confirmed
symptomatic  cCMV  infection  with  viral  detection  in  either  urine,  blood,  or
saliva within the first 3 weeks of life and an available FMC serum bank sample.
Symptomatic infection was defined as the presence of at least one CMV-related
symptom: intrauterine growth restriction (<-2SD), microcephaly (<-2SD),
thrombocytopenia  (<80 x  109/l), petechiae, hepatomegaly or splenomegaly,
calcifications in brain ultrasound, hepatitis (alanine aminotransferase
>100U/l),  or  SNHL.  A  serum  bank  sample  was  available  for  26  of  the  29
children diagnosed with symptomatic cCMV infection during the time period,
and these 26 children were included in the study.
Studies III and IV
We performed universal neonatal screening for cCMV infection in Helsinki
area hospitals (Naistenklinikka, Kätilöopisto, Jorvi Hospital, and Lohja
Hospital) from September 2012 to January 2015 to identify cCMV infants. The
screening was offered to all infants whose parents understood either Finnish,
Swedish, or English in order to read the study information leaflet.
The children who tested positive in the CMV screening were followed
prospectively. For all positive children, one healthy control was selected, and
the controls were matched according to the delivery date, gestational weeks at
delivery, sex, and neonatal care unit.
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4.2 METHODS
4.2.1 ANTIBODY ASSAYS (I, II, AND III)
Cytomegalovirus antibodies were measured from the FMC serum samples and
the antenatal serum samples of mothers of CMV-positive infants to evaluate
the type of maternal CMV infection, as presented in Table 7. In Studies I, II,
and III, IgG was measured with commercial assay Architect CMV IgG Reagent
Kit, Abbott Laboratories, Wiesbaden, Germany. In Studies II and III
additionally, IgM and IgG avidity were measured with commercial Architect
CMV IgM and Architect CMV IgG avidity assay. The avidity under 50% was
considered  low  and  over  60%  was  high  according  to  the  manufacturer’s
instructions. Avidities between 50% and 60% were considered a grey area with
unreliable interpretation [253, 254]. The FMC samples (Study I and II) were
tested  during  a  short  time  frame  per  study,  after  receiving  the  archived
samples. All samples were tested separately. The antibody assays for the
prospective screening study (III) were performed whenever a positive infant
was identified during the 2.5 years screening period.
Table 7. Type of maternal CMV infection: interpretation of antenatal antibody results
measured at the end of the first trimester.
IgG IgM
Non-primary Positive, high avidity Positive or negative
1st trimester or near conception Positive, low avidity Positive
Negative Positive
2nd-3rd trimester Negative Negative
4.2.2 SALIVA SAMPLES (III, IV)
Screening saliva samples were collected from newborns born in Helsinki area
hospitals from September 2012 to January 2015 during the first week of life.
Follow-up samples from screening positives were collected at 3 months and 18
months of age. After informed consent was received from parents, a Dacron
swab was placed in infant’s mouth and removed after saturation with saliva.
The swab was dried at room temperature, and dry swabs were stored at -20°C
Materials and Methods
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until shipped to the University of Alabama, Birmingham (UAB), USA, for PCR
analysis.
4.2.2.1 CMV real-time PCR (III, IV)
PCR analysis was performed in UAB, with a PCR test that was developed to
diagnose CMV infection in neonates [173, 176]. The ABI 7500 Real-time PCR
system (Applied Biosystems Inc., Foster City, CA) and AbsoluteTM QPCR Low
ROX Mix (ABgene USA, Rockford, IL) were used. Primers to detect the highly
conserved immediate early 2 exon 5 region were used. The sample was
considered positive if one or more genomic equivalents per reaction were
detected.
4.2.2.2 Genotyping for gB (UL55), gH (UL75), and gN (UL73) (IV)
CMV-positive screening saliva samples were further analysed for viral gB, gH,
and  gN  genotypes.  The  genotype  analysis  was  performed  in  UAB.  For
screening and follow-up samples, the evaluation for gB and gH was performed.
Glycoprotein  B  and  gH  genotype-specific  real-time  PCR  with  the  Taqman
platform was used [32, 255, 256]. The CMV-positive screening saliva samples
were also examined for genotype of gN. PCR was used to amplify the gN gene.
PCR  products  were  cloned  using  the  TOPO  TA  cloning  kit  (Thermo  Fisher
Scientific), and the colonies were screened for the presence of the gN insert.
The nucleotide sequences were compared with the previously published gN
subtype sequences (GeneBank accession numbers AF309971, AF309976,
AF309980, AF390773, AF309987, AF309997, AF310004) [41]. The
nucleotide sequences were aligned using the Bio Edit software [15, 257].
4.2.3 URINE CMV CULTURE AND PLASMA CMV PCR (III, IV)
In the prospective screening study, urine and plasma samples were collected
from screening positive infants at 3 months and 18 months of age. In-house
rapid  culture  method  was  used  to  test  for  detection  of  early  CMV  nuclear
antigen  by  immunofluorescence  test  in  the  urine.  The  plasma  sample  was
tested for viral load by commercial assay (COBAS AmpliPrep/COBAS Taqman
CMV test, Roche) according to the manufacturer’s instructions. The analytical
sensitivity of the assay is 56 IU/ml.
4.2.4 OUTCOME (II, III)
In the retrospective study of children with symptomatic cCMV, the outcome
data were collected retrospectively from the patient records (Study II). In the
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prospective screening study, data were collected prospectively in
appointments  at  3  months  and  18  months  of  age.  The  same  pediatrician
evaluated all the subjects during the visits (Study III).
4.2.4.1 Retrospective data collection (II)
The  outcome  of  children  with  symptomatic  CMV  infection  (Study  II)  was
evaluated based on clinical patient data files. Based on the clinical records, we
assessed the outcome on neurology, hearing, and ophthalmology.
Neurological  outcome  was  defined  as  normal,  mild  abnormality,  or  severe
abnormality. The neurology was considered normal if the neurological
performance  at  the  latest  follow-up  visit  was  appropriate  for  the  age.  Mild
abnormalities included learning difficulties, problems with attention, and
mild motor disturbances with normal communication abilities. Severe
neurologic abnormalities included cerebral palsy, intellectual disability, and
death. Hearing and ophthalmological outcomes were evaluated from the last
clinical follow-up visit.
4.2.4.2 Prospective data collection (III)
Neurodevelopmental outcome was assessed using Griffiths Mental
Development Scales, 1996 Revision, from birth to 2 years [258]. These scales
evaluate the development in five distinct areas: A locomotor, B personal-
social, C hearing and language, D eye-hand coordination, and E performance.
According to the test manual, the subquotient for each developmental section
and general quotient measuring the total development were determined.
An experienced audiologist evaluated the hearing of CMV-positive children
and healthy controls.  Testing was performed at  3 months and 18 months of
age  with  TEOAE.  It  evaluates  the  acoustic  response  to  a  sound  stimulus
produced  by  the  inner  ear.  It  tests  both  ears  separately  and  can  reveal
unilateral  hearing  losses.  At  18  months  of  age,  sound field  (SF)  audiometry
was performed. SF measures the behavioral response to frequency-specific
stimulus.  It  tests  both  ears  simultaneously  and  cannot  reveal  unilateral
hearing  loss.  However,  it  gives  a  good  assessment  of  functional  hearing
capacity.
An ophthalmologist examined the eyes of subjects at 3 months and 18 months
of age. Examination included fix and follow, contact and smiling, Hirschberg,
convergence, cover test, red reflex, and refraction. The fundus was evaluated
with indirect ophthalmoscope, including evaluation of optic nerve head, fovea,
and midperiphery.
Materials and Methods
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4.2.4.3 Fetal growth (II, III)
Intrauterine growth was evaluated from the birth measurements (i.e., weight,
height, head circumference), according to the national reference values [259].
4.2.5 STATISTICS
Stata versions 11.1 and 14.2 (StataCorp LP, College Station, TX) and IBM SPSS
Statistics version 22 (SPSS Inc., Chicago, IL) were used to perform statistical
analysis. Fisher’s exact or Pearson’s chi-squared test (ǒ2) were used to compare
categorical variables. Parametric linear variables were compared with the t test
and  non-parametric  linear  variables  with  the  Mann-Whitney  U  test.  The
proportions and prevalences were presented with 95% confidence intervals.
4.2.6 ETHICAL CONSIDERATIONS
The study protocols were approved by the coordinating ethics committee (I,
II), and ethics committee for women, children, and psychiatry (III, IV) in the
Hospital District of Helsinki and Uusimaa. In addition, the National Institute
for Health and Welfare approved the data collection from patient files in study
II.  All  studies  were  conducted  in  accordance  with  the  guidelines  of  the
Declaration of Helsinki. In Studies I and II, CMV antibodies were evaluated
from the archived early pregnancy samples from FMC serum bank, collected
after obtaining informed consent. The FMC steering group approved the study
protocols (I, II). A written, informed consent was obtained from the parents
before collecting CMV screening saliva samples from the infants (III, IV). The
CMV-positive infants and healthy controls were followed up according to the
protocol, enabling the early interventions such as hearing rehabilitation or
physiotherapy, if needed (III).
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5 RESULTS
5.1 MATERNAL SEROPREVALENCE OF CMV
ANTIBODIES IN FINLAND (I)
The changes of seroprevalence for CMV among Finnish pregnant women from
1992 to 2012 are presented in Figure 4.
Figure 4 The seroprevalence for CMV in 1992, 2002, and 2012 among Finnish pregnant
women. 200 samples per time-point were evaluated. CMV seroprevalence decreased from
84.5% (95% CI 78.7–89.2) to 71.5% (95% CI 64.7–77.6) between 1992 and 2012. Change
was statistically significant, calculated by Fisher’s exact test (p=0.007).
5.2 MATERNAL PRIMARY AND NON-PRIMARY
INFECTIONS AND CONGENITAL CMV INFECTION (II,
III)
The  type  of  maternal  CMV  infections  during  pregnancy  leading  to  birth  of
congenitally infected children in the studied retrospective and prospective
cohorts are presented in Figure 5. The antenatal serum sample drawn at the
end of first trimester was available for testing in 26 symptomatic cCMV
children  in  the  retrospective  cohort  and  38  children  in  the  prospective
Results
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screening cohort. In both cohorts, the maternal non-primary infections
dominate. The proportion of maternal primary infection in early pregnancy
was  higher  in  the  retrospective  cohort  of  symptomatic  children  (27%)
compared  to  the  screening  cohort  (16%);  however,  the  difference  was  not
statistically significant (p=0.277).
Figure 5 Proportions of maternal primary and non-primary infections in pregnancies leading
to congenital CMV in the studied retrospective and prospective cohorts.
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5.3 PREVALENCE OF CONGENITAL CMV INFECTION IN
FINLAND (III)
5.3.1 POPULATION IN SCREENING
A total of 19,868 neonates were screened for cCMV infection during the study
period  of  September  2012  to  January  2015.  Most  screening  samples  were
collected in the well-baby nurseries (98.3%) and minority in the basic neonatal
wards (1.7%). In addition, 70 samples were collected in the neonatal intensive
care unit (NICU). The sampling in the NICU was not representative due to low
yield of samples, and it is not included in the analysis. Approximately 54% of
infants born in the four study hospitals were screened. The screening
percentages in each hospital during the study period are presented in Figure
6.
Figure 6 The proportion (%) of CMV screened infants of all infants born in the four screening
hospitals (NKL=Naistenklinikka, KOS=Kätilöopisto Hospital, Jorvi Hospital, Lohja Hospital)
The demographic data were evaluated from the 9,167 mothers of screened
infants who attended the screening between October 1, 2012, and October 31,
2013.  The  data  and  comparison  to  the  general  population  in  Finland  are
presented in Table 8 [260].
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Table 8. Demographics of mothers of CMV-screened infants versus the population in
Finland.
Characteristics
Mothers of screened
infantsa General population
Born in Finland, % 88.1 89.8b
Born abroad, %
Europe, %
America, %
Africa, %
Asia, %
Australia or
New Zealand, %
11.9
7.3
0.6
1.4
2.6
0.03
10.2b
6.3b
0.4b
0.9b
2.5b
      0.03b
Primipara, % 38 41c
Mothers with ≥4 previous
deliveries, % 1.6 4.8c
Number of children in the family,
mean
1.86 1.75d
Married, % 66 58c
aEvaluated from 9,167 mothers screened between October 1, 2012, and October 31, 2013
bWomen aged 20-39 years living in Finland, 2013 (n=822,321) [260]
cLive births in Finland, 2013 (n=58,134) [260]
dTotal fertility rate, 2013 [260]
5.3.2  PREVALENCE OF CCMV
From  19,868  screening  samples,  56  were  positive.  One  screening  positive
infant  did  not  attend  any  further  follow-up  and  no  control  samples  were
collected. After control urine and saliva samples at age 3 months, 15 screening
positive  samples  proved  to  be  false  positives.  In  total,  40  infants  had
confirmed cCMV infection,  making the prevalence 2 out of  1,000 newborns
(95% CI 1.4–2.6 out of 1,000).
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Figure 7 Flowchart of the congenital CMV screening. After screening of 19,868 neonates, the
prevalence of cCMV was 2/1,000 (95% CI 1.4–2.6 out of 1,000)
The calculated prevalence in subpopulations according to mother’s country of
birth  is  presented  in  Table  9. We estimated the total number of screened
populations  per  continent  based  on  the  data  from  9,167  screened  infants
between October 1, 2012, to October 31, 2013. Due to low numbers, the 95%
confidence intervals are wide.
Table 9. Calculated prevalence of congenital CMV in Finland according to mother’s
country of birth.
Mother’s country of
birth
Positive cCMV in all
19,868 screened
Prevalence/
1,000a 95% CIb
All 40 2.0 1.4–2.6
Finland 34 1.9 1.3–2.7
Europe, not Finland 2 1.4 0.2–5.0
Asia 2 3.8 0.5–13.8
Africa 1 3.5 0.1–19.6
America 1 8.7 0.2–47.5
Australia and New
Zealand
0 – –
aCalculated based on data from 9,167 mothers screened between October 1, 2012, and
October 31, 2013
bBinomial exact
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5.3.2.1 False positives
Fifteen positive screening samples were regarded as false positives. Urine
CMV culture was negative at age 3 months in 14 children. Congenital infection
leads to prolonged CMV excretion in urine and is known to still be positive at
3 months [92, 261]. In the case of one false negative child, the 3-month urine
sample was not collected.
In 12 children, false positivity was confirmed. Four children had no CMV
antibodies at 3 months of age. In infants, the antibody status represents
maternal antibodies and the mothers of these children did not have antibodies
for CMV, thus also excluding the cCMV infection. Eight children, including one
child  with  no  urine  sample  collection  at  3  months  were  negative  for  CMV
antibodies at age 12 to 18 months. At this age, maternal antibodies had faded,
and lack of CMV antibodies in the children excluded congenital infection.
In  three  cases,  false  positivity  was  not  confirmed,  and  they  are  regarded  as
suspected false positives. In two cases with negative urine culture at 3 months,
no  confirmatory  antibody  sample  was  tested  after  fading  of  maternal
antibodies. One child with negative urine culture and negative saliva CMV PCR
at age 3 months had a positive urine culture and positive CMV antibodies at
18 months. She is considered as suspected postnatal infection. The laboratory
examinations of the false positive children are presented in Table 10.
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Table 10. Test results at 3 months and 12–18 months of age from the 15 children with
false positive congenital CMV screening samples. NT=not tested.
Case
At 3 months
At 12–18
months
Interpretation
Urine
CMV
culture
Saliva
CMV
PCR
CMV-
IgG CMV-IgG
1 - + + - Confirmed false positive
2 - - + -
3 - - - NT
4 - - + -
5 NT + + -
6 - - + -
7 - - - NT
8 - - + -
9 - - + -
10 - - - NT
11 - NT - NT
12 - + + -
13 - NT + NT Suspected false positive
14 - NT NT NT
15 - - + + Suspected false positive and
postnatally acquired infection
5.4 OUTCOME OF CONGENITAL CMV INFECTION (II, III)
5.4.1 OUTCOME OF SYMPTOMATIC CMV INFECTION (II)
5.4.1.1 Neonatal presentation
The  symptomatic  cohort  consisted  of  26  children  diagnosed  with  cCMV
infection in all university hospitals from 2000 to 2012. Mean gestational age
at birth was 37 +2 weeks (ranging from 29 +5 to 41 +4 weeks). The majority of
infants (18/26) were born at term, and eight of them were born prematurely
(ranging  from 29+5 to  35+4 weeks).  Growth  restriction  was  common,  58%
(15/26) had a birth weight less than -2.0 SD, and 28% (7/25) had a birth height
less  than  -2.0  SD.  Microcephaly  (head  circumference  less  than  -2SD)  was
found in 48% (11/23). Other symptoms during the neonatal period according
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to patient files were petechiae (n=9), thrombocytopenia (n=13), anemia (n=3),
neutropenia (n=2), leukopenia (n=2) hepato-/splenomegalia (n=12), elevated
transaminases or icterus (n=4), and hypotonia or abnormal
electroencephalogram (n=5).
5.4.1.2 Imaging
Brain ultrasound was performed for 23 infants during the neonatal period and
was  abnormal  in  61%  (14/23).  Cerebral  MRI  was  performed  for  13  infants
during the first year of life and was abnormal in 9 cases. Abnormal imaging
findings are presented in Table 11.
Table 11. Abnormal imaging findings in retrospective cohort of symptomatic congenital
CMV. (II)
Brain ultrasound n=23 Cerebral MRI n=13
Cysts or cystic abnormalities (n=8)
 caudothalamic sulcus
 periventricular
 lateral ventricles
 midline and occipitofrontal plexus
Calcifications (n=9)
 periventricular
 parenchymal
 thalamic
 basal ganglia
Dilated ventricles (n=6)
Dilated cortical liquor space (n=1)
Abnormal gyration (n=1)
Candle stick abnormalities in thalamus (n=1)
Lenticulostriatal vasculopathy (n=1)
White matter abnormalities (n=5)
 signal intensification
Cystic abnormalities (n=2)
Calcifications (n=5)
 periventricular
 cortical
 cerebellar
Dilated ventricles, thin parenchyma in
occipital and parietal lobes (n=1)
Abnormal gyration (n=2)
 cerebral
 cerebellar
Delayed myelinization (n=2)
5.4.1.3 Long-term sequelae
Based  on  the  clinical  files,  58%  (15/26)  of  retrospectively  evaluated
symptomatic children had some long-term disability suspected to be caused
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by the cCMV infection. Of the children whose mothers had had primary CMV
infections  in  the  early  pregnancy,  86% (6/7)  had  some long-term sequelae.
None  of  the  5  children  whose  mother  had  a  primary  infection  in  later
pregnancy developed any long-term sequelae. Of the children whose mother
had suffered from non-primary infection during pregnancy, 64% (9/14)
developed long-term sequelae.
The neurological outcome could be evaluated from clinical files in 24 children.
The average follow-up time was 21.7 months (ranging from 3 to 132 months).
One  premature  child  born  at  gestational  week  30+3  with  CNS  lesions,  and
respiratory distress syndrome, died at the age of 3 days. Neurologic outcome
was abnormal in half (50%, 12/24) of children. Severe disabilities appeared in
29% (7/24), and mild disabilities in 21% (5/24). If the mother had a primary
CMV  infection  in  early  pregnancy,  57%  (4/7)  of  the  children  suffered  from
severe neurologic abnormalities and 29% (2/7) from mild neurologic
abnormalities.  If  the  mother  had  a  non-primary  infection,  25%  (3/12)  had
severe  neurologic  abnormality  and  25%  (3/12)  had  mild  neurologic
abnormality.
Of the children with available hearing test results, SNHL was present in 42%
(8/19). The average follow-up time was 44.6 months (ranging from 5 to 132
months).  Of  the  children  whose  mothers  had  primary  infection  in  the  first
trimester 20% (1/5) had bilateral and 40% (2/5) had unilateral hearing loss.
Of  the  children  whose  mothers  had  non-primary  infection,  20% (2/10)  had
bilateral  hearing  loss  and  30%  (3/10)  had  unilateral  hearing  loss.  Three
children had hearing aids, and one of them needed a cochlear implant.
The data from ophthalmological follow-up were available for 18 children with
average follow-up of 21.7 months (ranging from 0 to 60 months). Two children
with cerebral palsy and severe intellectual disability had visual impairment.
5.4.2 OUTOME OF INFANTS IDENTIFIED IN THE CONGENITAL CMV
SCREENING (III)
5.4.2.1 Neonatal presentation
The universal screening was performed in well-baby nurseries and basic
neonatal wards. All CMV-positive children were identified in the screening.
None of the CMV-positive children had presented with apparent clinical
symptoms raising clinical suspicion of cCMV infection. Based on clinical
findings,  however,  10%  (4/40)  of  the  children  were  categorized  as  having
symptomatic  infection.  One  child  had  microcephaly  (-3.3  SD),  and  three
children had calcifications detected in the cerebral US. Birth measures and
Results
60
gestational  ages  at  birth  are  presented  in  Table  12.  One  child  was  born
prematurely at gestational week 36 +4, and all other infants were full-term.
Table 12. Characteristics of cCMV-positive infants in the screening study.
Characteristics Mean Range
Gestational age, weeks 39+4 36+4 to 42+0
Birth weight, kg 3.315 2.162 to 3.980
Birth height, cm 49.7 46 to 54
Head circumference, cm 34.5 30.0 to 36.5
Birth weight, SDa -0.48 -2.1 to +1.2
Birth height, SDa -0.21 -2.0 to +2.4
Head circumference, SDa -0.24 -3.3 to +1.6
Apgar 1 min 8.9 6 to 10
aPopulation-based reference [259]
5.4.2.2 Imaging findings
Cranial  ultrasound  was  performed  on  all  40  CMV-positive  infants  and  52
healthy  controls  at  3  months  of  age.  Examination  was  not  blinded.
Abnormalities were seen in 11/40 CMV-positive and 3/52 healthy controls.
The imaging findings of CMV-positive infants are presented in Table 13. Two
healthy controls had lenticulostriatal vasculopathy, and one had small
germinolytic cysts on US. MRI was performed at 6 months to 20 months of
age in 5 CMV-positive children on clinical indications: three children with
calcifications in US,  one child with microcephaly,  and one child with mildly
delayed motor development.
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Table 13. Imaging findings of CMV-positive children.
Abnormal brain ultrasound findings in
11/40 CMV positive
Abnormal cerebral MRI findings in 4/5
CMV positive
Calcifications (n=3)
 small/multiple small
Cysts (n=6)
 periventricular
 germinolytic cysts
 isolated plexus cyst
Lenticulostriate vasculopathy (n=4)
No findings (n=1)
Increased signal intensity in white matter
(n=2)
Small cysts (n=2)
 caudothalamic sulcus
 duplex cyst in corpus pineale
Calcifications (n=2)
 in anterior horn unilaterally
 thalamus
Polymicrogyria (n=1)
 in frontal lobes anterolaterally
5.4.2.3 Neurology at 18 months
The developmental outcome was evaluated at 18 months of age with Griffiths
Mental Development Scales from birth to 2 years. The outcome was compared
with  the  healthy  controls.  There  was  no  difference  in  general  quotient  or
quotient in any subscales at  18 months.  Griffiths quotients are presented in
Table 14.
Table 14. Griffiths Developmental Scales at 18 months old did not differ between
congenital CMV positive and healthy controls in any subscale or general quotient.
Griffiths quotients
cCMV positive
 mean (range)
Controls
 mean (range) pa
A Locomotor 100.8 (62–119) 100.5 (50–119) 0.715
B Personal-social 105.5 (72–124) 104.6 (63–124) 0.721
C Hearing and language 101.2 (77–127) 102.0 (79–125) 0.472
D Eye-hand coordination 103.2 (79–127) 101.7 (56–127) 0.650
E Performance 96.3 (73–123) 99.8 (50–122) 0.173
General quotient 101.0 (85–120) 101.6 (81–117) 0.557
aMann-Whitney U test
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5.4.2.4 Hearing at 18 months
Hearing was tested for 35 CMV-positive patients and 46 healthy controls at 18
months of age. Based on a combination of TEOAE and SF audiometry, none of
the children needed hearing rehabilitation (i.e., hearing aid or cochlear
implantation)  by  the  age  of  18  months.  Due  to  insufficient  cooperation  or
artefact  noises,  TEOAE  was  technically  unsuccessful  in  16/70  (23%)  ears
tested  in  CMV-positive  children,  and  12/92  (13%)  ears  tested  in  healthy
controls. Of the technically reliable measurements, the proportion of failed
TEOAEs  was  similar  in  CMV-positive  (4/54)  and  heathy  controls  (6/80)
(p=1.000).
5.4.2.5 Ophthalmology at 18 months
An ophthalmologist evaluated the 35 patients and 47 healthy controls at 18
months of age. No CMV-related pathologies were detected. One CMV-positive
child had significant hypertrophia, a physiological finding at 3 to 18 months of
age. One healthy control child had intermittent esotropia.
5.5 VIRAL SHEDDING (IV)
CMV shedding to saliva, urine, and plasma was measured at 3 months and 18
months of age in cCMV children identified in the screening. All tested urine
samples were positive for CMV culture at 3 months (40/40) and 18 months
(33/33)  of  age.  Saliva  samples  were  positive  for  CMV  PCR  in  all  3-month
samples (40/40) but only 24% (9/37) in 18-month samples. Plasma samples
tested at 3 months of age had positive CMV PCR in nearly half (19/40) but only
6% (2/34) at 18 months of age.
5.6 DISTRIBUTION OF GENOTYPES FOR CMV
ENVELOPE GLYCOPROTEINS H (UL75), B (UL55),
AND N (UL73) (IV)
CMV-positive screening saliva samples were genotyped for CMV gH (UL75),
gB  (UL55),  and  gN  (UL73).  Follow-up  saliva  samples  at  3  months  and  18
months of age were genotyped for gH and gB. Both two genotypes for gH (gH1
and gH2) and all four genotypes for gB (gB1, gB2, gB3, and gB4) were present
in our samples. All genotypes for gN except gN2 were present in our cohort
(gN1, gN3a, gN3b, gN4a, gN4b, and gN4c). Mixed infections were uncommon;
only two screening samples had two distinct genotypes for gH (6%) and one
sample for gN (4%). Results of genotyping are presented in Table 15.
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None  of  the  genotypes  for  gH,  gB,  or  gN  was  associated  with  symptomatic
infection, or neurologic outcome measured with Griffiths Mental
Development Scales at 18 months age.
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Table 15. Genotyping for CMV gH (genotypes gH1, gH2), gB (genotypes gB1, gB2, gB3,
gB4), and gN (genotypes gN1, gN2, gN3a, gN3b, gN4a, gN4b, gN4c) in CMV-positive saliva
samples in screening (gH, gB, and gN), and at 3 and 18 months old (gH and gB). Four
samples had new mutations resulting in amino acid changes in gN genotype that has not
been previously described (3bN1and 4aN1). NT=not tested NA=not amplified
Case
Screening saliva 3-month saliva 18-month saliva
gH gB gN gH gB
CMV
PCR gH gB
1 1 1 4c  NT NT
2 2 2 4b 2 2 -
3  NT NT NT 2 1 -
4 2 3 3b 2 3 + 1 4
5 1, 2 1  NT 2 1 -
6 1 1 1 NT NT -
7 1, 2 3 4c 2 3 -
8 NT  NT  NT NA 1 -
9 1 1 4b NT NT -
10 1 1 1 1 1 -
11 2 1 3b 2 1 -
12 1 3 3bN1 NA 3 -
13 1 2 NT 1 2 + 1 NA
14 2 2 NT 2 2 + 1 NA
15 2 1 NT 2 1 + NA 4
16 NA 1 NT 2 1 -
17 2 1 3b 2 1 -
18 2 3 4c 2 3 -
19 1 2 1 1 2 -
20 1 3 3a 1 3 -
21 2 1  NT 2 1 -
22 2 1 4c 2 1 -
23 1 2 3bN1 1 2 + 1 3
24 1 1 4c 1 1 -
25 1 1 1 1 1 -
26 1 1 4c 1 1 -
27 1 1 NT 1 1 -
28 1 1 1 1 1 -
29 1 1 1 1 1 + NT NT
30 2 1 NT 2 1 +  NT NT
31 2 1 4a NA 1 -
32 2 4 NT 2 4 -
33 2 3 1, 4aN1 2 3 -
34 2 3 3a 2 3
35 1 2 NT 1 2 + NT NT
36 NA 4 NT 1,2 4 -
37 2 3 4aN1 2 3 -
38 NA 3  NT 2 3 + NT NT
39 2 2 NT 2 2
40 NA NA NT 1 1 -
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6 DISCUSSION
6.1 CMV SEROPREVALENCE IN FINLAND AND
PREVALENCE OF CONGENITAL CMV
6.1.1 MATERNAL SEROPREVALENCE OF CMV
In a cross-sectional study (I) from randomly selected FMC samples from 1992,
2002, and 2012, we observed a significant decrease in the CMV seroprevalence
among  pregnant  women  from  84.5%  in  1992  to  71.5%  in  2012.  A  similar
decrease in CMV seroprevalence has been observed among pregnant women
in Germany and Japan,  and among 18- to 45-year-olds in Hong Kong [125,
262, 263].
Various factors could cause these changes. CMV infection has been shown to
be more common in persons with lower socioeconomic status [55]. Well-being
in Finland has improved during the recent decades. The income per household
increased by over 40% from 1992 to 2012 [260]. Living conditions have also
changed.  In  1992,  29%  of  inhabitants  were  living  in  crowded  situations,
defined by living in apartments with less than one room per person, compared
to  only  17.5% in  2012  [260].  These  factors  most  probably  contribute  to  the
decrease in seroprevalence.
Previously, two main factors have been hypothesized to have a major impact
on CMV prevalence in developed countries: the frequency of breast feeding
and  children’s  attendance  at  daycare  centers  [264].  CMV  is  secreted  to  the
milk of seropositive women; therefore, early infections through breast milk are
common and seropositivity is thus passed naturally between generations. On
the  other  hand,  children  acquiring  the  infection  during  early  years  of  life
continue  to  shed  the  infectious  virus  for  long  periods  of  time.  In  daycare
centers, these infections are efficiently spread through close contact to other
children and toys contaminated with CMV-positive excretions. Children
attending daycare have shown to shed CMV more often than children taken
care of at home [102-105]. Changes in daycare practices may influence
seroprevalence observed in mothers having more than one child, and later in
the next generations.
In Finland, however, the changes in breast-feeding practices obviously do not
explain the observed decrease in seroprevalence. According to postnatal
transmission through lactation, the feeding habits in the preceding generation
reflect the possible changes in seropositivity rates. In Finland, breast feeding
has been rising dramatically after its lowest years in the 1970s, when less than
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10% of 6-month-old children received breast milk [265]. In 1990 and 2000,
more than half of 6-month-olds were breast fed. In addition in 1995, only 26%
of  3-month-old  infants  were  exclusively  breast  fed  [266].  In  2010,  the
proportion  had,  however,  doubled  to  53%.  Although  the  length  of  breast
feeding has increased lately, the proportion of infants receiving any breast
milk has been over 90% since the 1990s [266].  The proportion of  breastfed
infants might be a more relevant factor influencing the seroprevalence than
the length of breast feeding, since the excretion of CMV to breast milk usually
takes place very early in the first weeks after delivery [143, 150, 267].
In Finland,  the proportion of  children attending daycare has risen in recent
decades. In 1985, 44% of children aged 1 to 6 years attended daycare outside
the  home,  in  contrast  to  63% in  2012  [268].  In  addition,  the  proportion  of
children attending daycare in larger daycare centers instead of smaller units
has risen from 56% to 76% [268]. These facts seem to suggest that the changes
seen  in  national  daycare  trends  do  not  explain  the  observed  changes  in  the
seroprevalence of CMV antibodies.
No  major  changes  in  the  demographic  characteristics  of  the  Finnish
population  have  been  reported  during  the  last  20  years.  The  proportion  of
children under 15 years of age was 19% in 1992 and 16% in 2012. Total fertility
rate  (i.e.,  estimated  number  of  live-born  children  for  one  woman  over  her
lifetime)  has  been  similar  in  recent  decades:  1.85  in  1992  and  1.80  in  2012
[260]. However, the proportion of immigrants has risen during the past few
decades.  In  2000,  only  4.2%  of  women  giving  birth  in  Finland  were  born
abroad.  In  2012,  the  proportion  had  jumped  to  9.1%  [260].  One  could
speculate that this change would possibly increase rather than decrease the
national rate of seroprevalence.
We did not evaluate the seroprevalence for CMV in the same population where
the prospective newborn screening for cCMV was performed. Instead, we
studied maternity cohort serum samples randomly selected from the whole of
Finland.  Screening  for  cCMV on  the  other  hand was  performed in  Helsinki
area  hospitals  (Kätilöopisto  Hospital  and  Naistenklinikka  in  Helsinki,  Jorvi
Hospital in Espoo, and Lohja Hospital). In earlier studies from Finland, the
seroprevalence among pregnant women was 70.7% in the Helsinki region and
56.3% in the Turku region. These samples were collected from 1992 to 1994
and  in  2000,  respectively  [53,  54].  In  the  Helsinki  area,  the  income  of  the
mother was associated with seropositivity [53]. Hence, the seroprevalence
ranged from 60.9% in higher-income areas to 76.4% in lower-income areas
[53]. Based on these figures from earlier studies [53, 54] and our own data, we
estimated that the current seroprevalence rate in the Helsinki area during
screening study was between 50%–80%.
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6.1.2 PREVALENCE OF CONGENITAL CMV
In  the  prospective  screening  study  (III)  from  the  saliva  of  infants,  the
prevalence  of  cCMV  was  0.2%  of  all  newborns.  It  is  known  that  the
seroprevalence of mothers is the most important factor affecting the
prevalence of cCMV in offspring [70]. In our Finnish cohort of 20,000 infants,
however, the prevalence was lower than we had estimated.
In other populations with around 70% seropositivity rate, the reported
prevalence of cCMV infections has clearly been higher, such as 0.5% in Sweden
and 0.4% in the USA [88, 91]. Similarly, in an earlier relatively small Finnish
study by Granström et al, 2% (3/148) of infants were CMV-positive after birth
[156]. In that study, the urine of the infants was screened after birth and three
infants  were  excreting  virus  during  the  first  days  of  life.  The  reported
prevalence  was  ten  times  higher  than  that  found  in  our  present  study.  The
reason for this difference is unclear, however, the small sample size (n=148)
may increase the likelihood of a coincidence.
In  our  screening  study,  most  of  the  sampling  (98.3%)  took  place  in  regular
wards of maternity hospitals and 1.7% in neonatal wards. Due to the low yield,
the  data  collected  from  the  NICU  are  not  included  in  the  analysis.  This  is
important to take into account when interpreting our findings, since the
prevalence of cCMV has been shown to be higher among children admitted to
NICUs [70, 269, 270]. Thus, our prevalence rate of 2 in 1,000 represents the
prevalence in apparently healthy infants, or infants with milder problems, who
are not admitted to NICU. In a large screening study performed in 25 study
sites in Japan, the prevalence for cCMV was 3.1 in 1,000 in the whole cohort
[93]. The prevalence was, however, only 2.4 in 1,000 among the 14,642
children screened in the primary obstetric clinics and municipal hospitals, in
contrast  to  4.7  in  1,000  in  the  university  hospitals  or  the  governmental
hospitals that care for referrals. We can only speculate whether performing the
universal screening in the NICU would have affected our findings.
Raising awareness of CMV and simple hygienic precautions have shown some
effect in preventing primary infections in seronegative women [239]. Revello
et al found significant reduction in seroconversions among pregnant women
who were instructed to wash hands frequently, not to kiss their children on the
mouth,  or  to  share  utensils,  food,  drinks,  or  washcloths  with  the  children
[239]. Seroconversions occurred in only 1.2% (4/331) in the intervention
group  compared  to  7.6%  (24/315)  in  the  group  without  intervention  [239].
Another observational study reported lower seroconversion rates after 12
weeks  gestation  (0.19%)  than  in  early  pregnancy  (0.42%).  All  seronegative
women were instructed about CMV and the routes of transmission around 12
weeks of gestation, which could have resulted in lower transmission after
counselling  [238].  The  study  by  Adler  et  al,  however,  showed  similar
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seroconversion rates (7.8%) among women receiving and not receiving
information on CMV [237]. Although there is no available data on preventing
non-primary CMV infections, the same measures could most likely prevent re-
infections caused by new viral strains. Prevention of relapsing infections
caused by reactivation of latent strains is of course impossible.
In Finland, the mothers of toddlers have been advised to prevent saliva contact
with their offspring. These measures have not been taken to prevent CMV
infection but to prevent transmitting Streptococcus mutans, the causative
organism of caries. Similarly, parents have been advised not to share utensils,
or food, or drinks with their toddlers. Since these measures showed to have
some efficacy in one study in reducing seroconversions, they may play a role
in the low prevalence of cCMV in our cohort [246].
6.1.3 FALSE POSITIVE SCREENING SAMPLES
In Study III, the proportion of false positives was high (15/55). The screening
samples were regarded as false positives if the confirmatory CMV urine culture
tested at 3 months was negative. The false positivity could be confirmed in 12
children with no CMV antibodies either at 3 months of age or later (Table 10).
This high frequency of false positive samples is in line with the recent study by
Leruez-Ville et al [85]. In their study, 41% of the screening samples were false
positives. One obvious reason for this phenomenon is the PCR tests, which are
too sensitive. Our findings emphasize the fact that confirmatory samples are
of paramount importance whenever screening is based on PCR. One reason
for these findings may also be that viral DNA contaminates the secretions in
the birth canal or breast milk [101, 143-150]. In our study, four of the children
who gave false positive samples (4/15, 27%) had no antibodies at 3 months of
age. At this age, the antibodies measured reflect mainly maternal antibodies
transferred  transplacentally  during  the  third  trimester  of  pregnancy.  This
means that the proportion of seronegative mothers was the same as estimated
to be in the population,  indicating the source of  false positive results  is  not
necessarily maternal. Since shedding of CMV is very common, one potential
source  of  contaminating  DNA may  also  be  the  nurses  who  took  care  of  the
infants and sampled the salivas.
6.1.4 POSSIBLE ACQUIRED INFECTIONS
In our protocol, the control samples (urine, saliva and serum) were drawn first
at  3  months  of  age.  Some  children  could  have  acquired  the  CMV  infection
during the first 3 months of life, which may have influenced our results. Thus,
it  is  impossible  to  differentiate  cCMV  from  acquired  CMV  at  the  age  of  3
months. Therefore, in future studies, the follow-up samples should be taken
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earlier, preferably before the age of 3 weeks. However, in our setting, earlier
sampling was not possible. The screening saliva samples were analyzed in the
UAB in the USA, and due to the time required for sample logistics, the results
were not available until 1-2 months of age. Therefore, the control sampling was
not performed before the follow-up visit at 3 months.
We observed the same genotype (gB and gH) in both the initial sample taken
at birth and later in the control sample at the age of 3 months in all 34 children
with serial saliva samples genotyped. This confirms that the same viral strain
was detected in screening and 3-month samples. However, it does not exclude
the contamination from the maternal secretion and postnatal infection from
maternal source with same strain.
6.2 OUTCOMES OF CHILDREN WITH CONGENITAL
CMV
6.2.1 HEARING LOSS
To  our  surprise,  the  outcome  of  the  CMV-positive  children  (n=40)  in  our
cohort identified in the screening (III) did not differ from that of the controls
at the age of 18 months. None of the 40 infected children had bilateral hearing
loss and none needed hearing rehabilitation. This was an unexpected finding
since in other similar screening studies bilateral hearing loss was detected in
6%–13.3%  [86,  188]  of  the  infants.  The  expected  number  of  infants  with
bilateral hearing loss in our cohort of 40 positive infants would, according to
the  literature,  have  been  2  to  5  children.  The  reason  for  this  discrepancy
remains open. In our mind, the low numbers of hearing deficits in our study
at the age of 18 months were not due to technical errors or low sensitivity of
the hearing tests used. We used the TEOAE combined with SF audiometry at
18 months of age. These methods are known to be both sensitive and specific
in  detecting  bilateral  hearing  losses  requiring  hearing  aids.  However,  some
cases  of  unilateral  hearing  losses  may  have  remained  unnoticed,  due  to
insufficient cooperation with the children. TEOAE measures the responses
from ears separately. However, it may be sensitive to artefact noises from the
environment. If the child refuses to keep the sensors in the ears or fails to be
quiet  during  the  evaluation,  the  results  can  be  unreliable.  In  the  SF
audiometry, the behavior response to sound stimuli is observed. The hearing
from both ears is evaluated simultaneously, and unilateral hearing loss can
therefore not be excluded by behavioral  SF audiometry.  On the other hand,
this test gives good insight into functional hearing. In the future, later follow-
up  of  this  cohort  will  add  information  about  the  late-onset  and  progressive
hearing losses in these children.
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Hearing losses have been reported to occur equally  often after  primary and
non-primary infections [198, 219]. However, the SNHL has been more often
severe  and  bilateral  after  primary  infections  [198].  The  high  proportion  of
children infected after maternal non-primary infection (53%) in our
prospective cohort may be one explanation for the favourable hearing outcome
observed in our screening study.
Boppana et al observed higher proportion of premature infants (33%) among
the  children  with  cCMV  and  hearing  loss  than  cCMV  and  normal  hearing
(9%)[187].  Although  the  screening  was  performed  in  basic  neonatal  wards,
where most preterm infants born after 32 gestational weeks are taken care of,
premature infants admitted to NICU are not presented in our screening. This
may have contributed to our finding of favourable hearing outcome.
In the retrospective cohort of symptomatic cCMV children born between 2000
and  2012  (II),  the  hearing  loss  was  much  more  frequent  than  among  the
screened children and appeared in 8/19 (42%) of  children who had hearing
tests results reported in the clinical files. This is in line with the literature [78,
86, 181, 186, 187, 192, 194, 197, 271, 272]. The hearing losses in our
symptomatic cohort were in most cases unilateral (5/8). It should be noted,
however, that the proportion of hearing loss may be an overestimation. The
outcome of these patients was collected from the patient files, and in the case
of some of the children (7/26), no information on any hearing evaluations was
available. Furthermore, those CMV-infected children with normal hearing
were  more  likely  the  ones  who  were  not  properly  followed.  In  Finland,  all
children are routinely followed in child health clinics where their  hearing is
also regularly evaluated. Therefore, those children who developed late-onset
hearing  losses  would  most  likely  have  been  remitted  to  further  evaluations.
Thus, we believe that the children who were not followed had normal hearing.
6.2.2 OPHTHALMOLOGY
In our prospective cohort (III), no CMV-related ophthalmological findings
were  present.  Visual  impairment  occurred  in  2/18  (11%)  of  children  in  the
retrospective cohort (II) of symptomatic infants, both severely neurologically
affected  children.  This  was  consistent  with  previous  studies  since
ophthalmological findings have been infrequent and mild among
asymptomatic infants [208, 209].
6.2.3 NEURODEVELOPMENTAL OUTCOME
In  Study  III,  the  neurodevelopment  of  cCMV  children  (n=37)  and  healthy
controls  (n=51)  was  evaluated  by  the  Griffiths  Developmental  Scales  at  18
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months of age. We could not find any differences between the infected children
and the healthy controls. In previous studies, neurodevelopmental sequelae
have been observed in 0%–14.2% of the evaluated children [84, 92, 181, 222,
223, 273, 274]. However, these cohorts were small (n=12–89). In a recent
meta-analysis by Bartlett et al, no inferiority in the neurodevelopmental
performance  could,  however,  be  observed  in  asymptomatic  cCMV  infants
when compared to healthy controls [201].
The Griffiths scales evaluate five distinct areas of neurodevelopment:
locomotor, personal-social, hearing and language, eye-hand coordination, and
performance. Two previous studies evaluated children with cCMV and healthy
controls with Griffiths scales. In a screening study from the early 1980s, Pearl
et al evaluated children with cCMV and healthy controls with Griffiths scales
at 2 years of age [204]. They did not find any difference when they compared
the children with no neurological symptoms (n=36) and the healthy controls
(n=74) [204]. Ivarsson et al, similarly, did not find a difference in Griffiths
scales at 21 months of age when comparing 32 children with cCMV but without
neurological symptoms or SNHL and 51 healthy controls [207]. Our analysis,
however, included all infants identified in the screening, including the ones
defined  as  symptomatic  children  based  on  either  microcephaly  (n=1)  of
calcification  in  the  ultrasound  (n=3).  In  Pearl’s  analysis,  no  difference  was
observed  if  the  infants  with  neurological  symptoms  were  excluded.  They
observed, however, significantly lower scores among the 5 children who had
developed neurological abnormality or SNHL; not all of these symptoms were
present at birth [82, 204]. In Ivarsson’s study, none of the children identified
in the screening had had neurological symptoms at birth. However, by the age
of one year, 7/42 children had developed neurological symptoms or SNHL and
they had been excluded from the analysis [207].
Our finding of favourable outcome may be linked to the fact that the children
admitted to the NICU were not screened. It is possible that some sick infants
with non-specific symptoms related to CMV could have been missed.
On the other hand, the neurodevelopmental outcome in our retrospective
cohort of symptomatic children was no doubt abnormal: half (12/24, 50%) had
clear findings. In most of those cases (7/12), the children were severely
affected, whereas only 5 of them (5/12) had only minor abnormalities. These
findings were in line with the previous literature [96, 199, 200].
Our findings based on these two cohorts emphasize the fact that the outcome
of  cCMV  infection  can  be  very  variable.  Symptomatic  infection  is  a  serious
condition, with a very high morbidity. On the other hand, the children without
any symptoms at birth seem to have a good prognosis. The infection was very
rare  in  our  population.  This  conclusion  could  be  drawn  both  from  our
screening  study  with  a  low  prevalence  of  2  in  1,000  and  also  from  the
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retrospective study with only 29 symptomatic cCMV-infected children
recognized during the 12-year period from all university hospitals in Finland.
Although symptomatic CMV infection could be somewhat more frequent as we
may have missed some children in the register-based retrospective cohort (II),
the  numbers  were  still  very  low  in  a  country  of  5.5  million  inhabitants.  In
addition, no severely affected symptomatic children were identified during the
prospective screening from September 2012 to January 2015 (III). This
substantially influences the outcome results from the screening study.
6.2.4 PRIMARY AND NON-PRIMARY INFECTIONS AND CONGENITAL
CMV
We were also interested in the type of maternal CMV infection, that is, whether
the  infection  of  the  child  was  associated  with  a  maternal  primary  or  non-
primary infection during pregnancy. The nature of the infection was based on
the  maternal  serum sample  drawn for  other  screening  purposes  during  the
first trimester. The definition of a non-primary infection was the presence of
high  avidity  IgG  in  the  early  pregnancy  samples.  The  definition  of  primary
infection was either presence of low avidity IgG with IgM (primary infection
in the first trimester) or no CMV antibodies (primary infection after the first
trimester) in the early pregnancy samples. Interestingly, the proportion of
non-primary  infections  was  almost  identical  in  both  cohorts:  54%  in  the
retrospective cohort of symptomatic infants (II) and 53% in the prospective
cohort of asymptomatic infant (III).
In our retrospective cohort (II), nearly two-thirds (64%, 9/14) of children who
acquired the infection after a maternal non-primary infection had long-term
sequelae. Neurodevelopmental outcome was reported in 12 children infected
after maternal non-primary infection and a quarter of those (25%, 3/12) had
severe neurologic impairment. Mild impairment occurred in 3/12, and half of
the children (6/12) infected after maternal non-primary infection had normal
neurology.  Long-term  sequelae  occurred  in  the  majority  (86%,  6/7)  of  the
children infected after maternal primary infection in the first trimester (II).
Interestingly, none of the 5 children whose mother had primary CMV infection
in  the  second  and  third  trimester  had  any  sequelae.  Our  cohort  is  small.
However,  a  recent  retrospective  study  by  Faure-Bardon  et  al  with  a  large
population  showed  similar  results  confirming  our  findings  [275].  In  their
study,  none  of  the  85  children  who  were  infected  after  maternal  primary
infection in the second or third trimester had any sequelae, in contrast to 32%
(35/108) after primary infection in the first trimester.
On  the  other  hand,  6  mothers  in  our  prospective  screening  cohort  had
experienced primary CMV infection in early pregnancy. None of the children
were severely affected (III). In these cases, however, the transmission to fetus
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may  have  occurred  only  later  in  the  pregnancy.  Our  findings  confirm  the
earlier understanding that both primary and non-primary infections during
pregnancy may cause severe long-term sequelae [198, 200, 208, 216-219].
We believe the described studies resulted in valuable information with clinical
importance.  Although  we  found  cCMV  to  be  rare,  CMV  is  a  common  virus
circulating in the population. Awareness of the possible risk for the developing
fetus may be a real fear for families. We hope that our studies help healthcare
personnel in counselling parents about CMV infection during pregnancy.
Psychological stress has been associated with higher vertical transmission
rates  in  primary  CMV  infections  [276].  Our  results  of  mainly  favourable
outcome might lessen the inevitable stress among pregnant women suffering
from CMV infection during pregnancy.
6.3 VIRAL SHEDDING AND GENOTYPES
6.3.1 GENOTYPES FOR GB, GH, AND GN AND OUTCOME OF
CONGENITAL CMV
CMV is  a  ubiquitous virus with a wide spectrum of  disease.  The majority of
congenitally infected infants recover without sequelae. However, some infants
are severely damaged due to the infection. The factors affecting the virulence
of  the  microbe  are  not  clear.  The  wide  genetic  variability  of  certain  genes
makes it possible to differentiate genotypes among the CMV populations.
Genes encoding for proteins involved in the immune responses, such as the
envelope glycoproteins, have been hypothesized to affect the virulence [12]. In
previous  studies,  the  association  of  certain  strains  with  pathogenicity  and
worse outcome, however, has been controversial [15, 21, 22, 25, 26, 34, 277-
284].  In  addition  to  genes  encoding  for  envelope  glycoproteins,  there  are
numerous other genes that have an important role in helping the virus to elude
immune response of the host, such as genes interfering with the function of
major histocompatibility complex, genes involved in inducing apoptosis, and
genes manipulating cytokine signaling [285]. In our studies, however, these
other genes were not studied.
In line with other studies, our prospective study (IV) showed no association
with  any  of  the  gH,  gB,  or  gN  genotypes  and  the  symptomatic  infection  or
severity of the disease [15, 21, 22, 34, 277-282]. Similarly, neurodevelopmental
outcome measured with Griffiths Developmental Scales could not be
associated with any particular genotype.
In most studies, including ours, the number of subjects has been very small.
This makes it difficult to draw conclusions about the associations of individual
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genotypes with clinical outcome. In a cohort of 93 cCMV infants in Italy, gN1
genotype  was  significantly  more  common  among  children  with  a  good
prognosis  [44].  In  that  study,  most  of  the  children  (62/93,  67%)  were
symptomatic.  However,  none  of  the  gN  genotype  was  significantly  more
common  among  symptomatic  than  asymptomatic  children  [44].  In  a  more
recent  study  from  the  same  author  with  74  subjects,  gN4  genotype  was
associated  with  symptomatic  infection,  and  gN1  and  gN3a  genotypes  with
asymptomatic infection and favourable long-term outcome [26]. In a Spanish
study  of  18  symptomatic  and  18  asymptomatic  children  with  cCMV,  gN1
genotype was associated with neurological findings at birth, even though it was
not associated with abnormalities in imaging findings [283].
In an American cohort of 32 asymptomatic and 22 symptomatic children, the
gB3 genotype was significantly more common among children with no
symptoms at birth [284]. However, this can also be explained by geographical
selection  bias  from  cohorts  because  in  that  study  the  most  asymptomatic
children  were  recruited  from  Iowa  and  the  majority  of  the  symptomatic
children from Texas, and local genotypes circulating in the various societies
may be different [284]. In a Spanish cohort of 36 newborns and 10 aborted
fetuses with cCMV, gB2 genotype was significantly associated with the
presence of  abnormal imaging findings,  and gB4 was associated with better
prognosis [283]. Half of the newborns in that cohort were symptomatic [283].
However, in most of the published studies, no association of any gN, gB, or gH
genotype with clinical presentation or long-term outcome has been observed
[15, 21, 22, 34, 277-282].
In  our  study,  however,  the  infants  were  mostly  asymptomatic,  and  the  four
infants who were categorized as symptomatic had mainly mild unapparent
symptoms. Only one child had microcephalus, and three other children were
categorized as symptomatic because of calcification in the brain ultrasound.
All had a favourable outcome at 18 months of age. Based on this population,
we cannot draw conclusions on the association of any genotype in the severe
affision.
6.3.2 GENOTYPE DISTRIBUTION (GB, GH, GN)
The  genotype  distribution  of  gB,  gH,  and  gN  genotypes  in  our  cohort  of
screened infants (IV) resembled that of other cohorts from other populations
around the world [15, 21, 26, 27, 33-36, 277-279, 281-283, 286-288]. Most
earlier studies of genotypes in cCMV populations have reported findings from
clinical  samples  of  mostly  symptomatic  infants  or  convenience  samples  of
larger screening-based cohorts. It is interesting that in all cohorts the gH1 and
gH2  genotypes  were  almost  equally  distributed,  regardless  of  whether  the
cohort  consisted  of  mainly  clinical  samples  from  symptomatic  infants,  or
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included mainly asymptomatic  children identified in screening [15,  34,  277,
279]. More variation occurred in the distribution of gB and gN genotypes [15,
21, 26, 27, 33, 35, 36, 277-279, 281-283, 286-288]. In most cohorts, including
our cohort, the gB1 was most common genotype in nearly half of the cases [21,
22, 27, 277, 279, 281-284, 286, 287, 289]. The gN genotypes were distributed
evenly, with no domination of any strain in any of the cohorts [15, 26, 35, 44,
277, 283]. The CMV strains identified in our cohort most likely present just
the strains circulating within our society and fail to explain the low incidence
of infections and disease burden in our population.
6.3.3 VIRAL SHEDDING
We also evaluated the length of viral shedding in children in the prospective
cohort (IV). The shedding was clearly more persistent in urine than in saliva.
At  18  months  of  age,  all  (33/33)  cCMV-positive  children  shed  virus  to  the
urine, in contrast to only 24% (9/37) who tested positive in CMV PCR in the
saliva. This is in line with previous studies that showed that secretion of the
virus  to  urine  lasted  longer  than  to  saliva  [81,  223,  290].  Forner  et  al  also
studied the kinetics of CMV DNAemia in serial blood samples of cCMV infants
[223]. Their finding was similar to our cohort: half of the children had CMV
DNA detected in the blood at 3 months of age.
Salivary shedding among toddlers is  an important contributor to horizontal
transmission of the virus. When prevention strategies are considered among
infants and toddlers, it is clearly more difficult to prevent contact with saliva
and oral secretions than urine. It is much easier to recommend hand washing
after every diaper change than urge hand washing after every sneeze, cough,
or  handling  with  saliva-contaminated  toys.  Hand  washing  is  effective  in
preventing transmission from hands after contact with CMV-positive
secretions [291]. In a study evaluating the survival of CMV, viable virus could
be recovered from unwashed hands in almost all (18/20) hands one minute
after the inoculation. At 15 minutes after inoculation, the virus could still be
cultured  from  nearly  a  quarter  (4/20)  of  tested  hands.  However,  washing
hands with either plain soap, antibacterial soap containing benzalkonium
chloride, or water only eliminated viable viruses from all tested hands [291].
The CMV is not a very contagious virus, and transmission through respiratory
droplets  is  unlikely.  Direct  contact  with  secretions  containing  the  virus  is
needed  for  transmission.  Toddlers  excreting  the  virus  to  saliva  may
contaminate the environment more efficiently compared to children excreting
the virus to urine.
The detection of CMV viruses in the saliva of healthy children with no clinical
symptoms of CMV infection is common [102, 103, 105, 292]. In a French study,
a fifth (80/369,  21.7%) of  young children attending the emergency unit  and
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half  (133/256,  51.9%)  of  children  attending  daycare  centers  were
asymptomatic  carriers  and  shed  CMV  in  saliva  [105].  Other  similar  studies
executed in daycare center surroundings have shown CMV excretion to saliva
in 45% (13/29), 10% (4/39), 10% (4/41), and 22% (12/54) of healthy children,
respectively [102, 103, 292]. In our study, 24% of cCMV children tested saliva-
positive at 18 months of age, which is of the same magnitude as reported in the
literature among healthy children. This emphasizes the fact, that in healthcare
settings, the cCMV infants should be treated with standard hygienic
precautions, as any other children. In conclusion, to prevent occupational
transmission  of  CMV  from  infants  and  children  to  daycare  or  healthcare
personnel,  all  children  should  be  treated  as  potential  sources  of  infectious
agents. Thus, it is important to follow universal precautions at all times
regardless of the CMV status of the child or patient.
6.4 PUBLIC HEALTH SIGNIFICANCE
The burden of cCMV in Finland was low. Based on our findings and previous
literature, approximately 11 to 15 children with permanent long-term sequelae
due to the cCMV infection are born in Finland annually (Figure 8).
Figure 8 An estimated disease burden of congenital CMV infection in Finland, based on
literature and our results in Studies II-III. The prevalence of congenital CMV was 0.2% in the
prospective Study III and 10% of infected infants were symptomatic. Long-term sequelae
appeared in 58% of symptomatic infants in the retrospective cohort in Study II. In the
literature, it is estimated that 5%-10% of asymptomatic infants will have long-term sequelae,
not confirmed by our 18-month follow-up in Study III.
Discussion
78
6.5 ETHICAL CONSIDERATIONS
Screening of apparently well children for a potentially severe condition has
ethical considerations, especially in the case of a condition with no effective
intervention  to  prevent  long-term  sequelae,  as  is  the  case  with  cCMV.  One
major issue is the anxiety the family of a CMV-positive infant may experience.
Our response to this potential concern was to give the families access to the
appropriate and correct information. We did our best to inform the families as
appropriately  as  possible  from  the  beginning  of  the  study.  The  families  got
both written information and contact information. A trained pediatrician (LP)
met  all  the  families  and  was  available  for  questions  by  phone  before  the
appointment. In addition, the cCMV-positive children were followed up very
closely and regularly. The rehabilitative interventions, such as hearing, visual
rehabilitation,  or  physiotherapy,  were  available  for  any  child  who  needed
them.
6.6 STRENGTHS AND LIMITATIONS
Our study provides comprehensive insight into the current situation of cCMV
in  Finland.  The  population-based  screening  of  19,868  infants  and  the
prospective follow-up of 40 infected infants and 54 healthy controls comprised
a  unique  cohort  of  an  unselected  population  (III).  All  children  born  in  the
Helsinki area were eligible for screening. The adherence to follow-up was
good.  The neurologic follow-up was completed by the majority of  the CMV-
positive (37/40, 92.5%) and healthy controls (51/54, 94.4%). The audiologic
follow-up  was  completed  by  most  of  the  CMV-positive  (35/40,  87.5%)  and
healthy controls (46/54, 85.2%). Similarly, the ophthalmologic follow-up was
completed by most of the CMV-positive (35/40, 87.5%) and healthy controls
(47/54, 87.9%).
The prevalence of cCMV was only 0.2%. When the study was designed in 2011,
we estimated the prevalence to be higher. Based on the literature on other
populations with similar seroprevalence of CMV, we calculated the prevalence
to be 0.4%–0.5% in the Finnish population [88, 173]. If that would have been
the case, our study would have identified 80–100 cCMV-positive infants
instead of the 40 children diagnosed.
The same clinician (LP) carried out the pediatric  examination including the
Griffiths Developmental evaluation of all children who participated in the
prospective study. These evaluations were, however, not blinded. In our
opinion, such a blinding would have been unethical. We felt that it was crucial
for the families of cCMV-positive children to meet a pediatrician at every visit
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who was ready to face their questions regarding the infection and the whole
study. Blinding would have made such consultations impossible.
The control samples from screening-positive infants were collected at 3
months of age. After perinatal and postnatal infections, viral shedding begins
after 3 weeks of incubation. Thus, in our study we could not definitely exclude
that some children in our study would have acquired the infection postnatally.
As the percentage of false positive screening samples was high (15/55), earlier
sampling would have been better.
In the retrospective study of symptomatic infants, the outcome data were
collected  from  clinical  files  of  different  hospitals  (II).  This  source  of
information contains risk for bias. Missing and inaccurate data were common,
and  the  location  and  identification  of  patients  were  incomplete;  in  other
words, we certainly missed some patients.
We evaluated the seroprevalence for CMV in 600 pregnant women at three
time points: 1992, 2002, and 2012. The sample size of each cohort was only
200 per year. Although the samples were selected randomly from the FMC, it
is possible that some selection bias in the population at different time points
could have an effect on the outcome. However, since we observed a very linear
decrease in seroprevalence from 1992 (84.5%) to 2002 (77.5%) and to 2012
(71.5%), we believe the data reliably represent a trend of decreasing
seroprevalence for CMV in our community.
6.7 FUTURE CONSIDERATIONS
It should be recognized that examining higher cognitive abilities at the age of
18  months  is  challenging  and  that  further  studies  performed  with  older
children are more informative. A later follow-up of the cCMV cohort identified
in  the  screening  will  give  more  information  on  the  long-term  cognitive
outcome and identify the children with later-onset hearing losses.
In our studies the CMV-positive samples were evaluated for only three genes
encoding for envelope glycoproteins of the virus. The new next-generations
sequencing methods, however, would give much more data on the sequence
variation among different CMV populations [12, 293]. It could be interesting
to  compare  the  CMV  strains  identified  in  our  screening  to  other  CMV
populations with these sensitive technologies.
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6.8 CONCLUSIONS
1. Seroprevalence for CMV among pregnant women in Finland decreased
from 84.5% in 1992 to 71.5% in 2012. (I)
2. The  prevalence  of  the  cCMV  infection  was  only  2  out  of  1,000.  The
outcome of infected infants identified in the screening did not differ
from the healthy controls at 18 months of age. (III)
3. The  outcome  of  the  26  children  with  symptomatic  cCMV  diagnosed
during  the  12-year  study  period  covering  all  national  university
hospitals was poor; 58% of them had long-term sequelae in later follow-
up. The main problems were SNHL and neurological impairment. (II)
4. Maternal  CMV infections  were  non-primary  in  more  than  half  of  the
cases in both asymptomatic and symptomatic cCMV infections. Long-
term sequelae among cCMV-positive nfants occurred after both
primary and non-primary maternal infections. (II, III)
5. In Finland, the viral genotype distribution for genes encoding for viral
envelope glycoproteins gH, gB, and gN was similar compared to other
cohorts in the literature. Thus, the discovered genotypes do not explain
the low burden of cCMV in our population. CMV shedding in urine was
more prolonged than to saliva among congenitally infected children.
(IV)
In  summary,  the  disease  burden  of  cCMV  in  Finland  was  lower  than  we
estimated. The low prevalence of cCMV and the good clinical outcome of the
asymptomatic infants suggests to us that universal screening of Finnish
children seems unwarranted at the moment.
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